Sodium channel regulator and application thereof

CN119731169APending Publication Date: 2025-03-28SHANGHAI HUILUN BIOLOGICAL TECH CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380061834.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-31
Filing Date
2023-08-28
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

Existing Nav 1.8 small molecule inhibitors suffer from poor selectivity and pharmacokinetic data in the treatment of pain, resulting in low bioavailability and difficulty in effectively relieving chronic pain.

Method used

A novel type I compound, comprising its pharmaceutically acceptable salt, stereoisomer, and racemate, has been developed to selectively inhibit the voltage-gated sodium channel Nav 1.8 through specific structural design for the treatment of pain and other related conditions.

Benefits of technology

It achieves highly selective inhibition of Nav 1.8, improves the efficacy of pain treatment, and enhances the bioavailability and ability of the drug to treat pain.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a sodium channel regulator and application thereof, and the sodium channel regulator provided by the invention has a brand new structure and has an excellent in-vitro inhibition effect on Nav1.8. The compound or the pharmaceutically acceptable salt thereof can be used for treating sodium channel related diseases, including pain, multiple sclerosis, fibula amyotrophy, incontinence, pathological cough, arrhythmia and the like.
Need to check novelty before this filing date? Find Prior Art

Description

A sodium channel regulator and its application

[0001] This application claims priority to Chinese patent application No. 202211036306.3 filed on August 28, 2022, Chinese patent application No. 202211374105.4 filed on November 3, 2022, and Chinese patent application No. 202310334077.1 filed on March 31, 2023. This application incorporates the entirety of the aforementioned Chinese patent applications. Technical Field

[0002] The present invention relates to the field of medicine, and in particular to a sodium channel modulator, a preparation method thereof, and therapeutic use thereof in treating diseases. Background Art

[0003] Pain is a complex sensation, usually an uncomfortable feeling caused by physical injury, illness or adverse external stimuli. For the needs of clinical research, the International Association for the Study of Pain (ISAP) defines pain as "an unpleasant sensory and emotional experience, often accompanied by actual or potential tissue damage." Pain, as a warning signal, can alert the body to potential dangers and plays an indispensable protective role in normal life activities. Pain is also a common clinical symptom. After the external stimulus that causes pain disappears, intense or persistent pain can cause physiological dysfunction and seriously affect the quality of life of the living organism. Data show that about one in five people worldwide suffers from moderate or severe chronic pain.

[0004] Pain originates from nociceptors in the peripheral nervous system. These are free nerve endings widely distributed throughout the skin, muscles, joints, and internal organs. They convert thermal, mechanical, or chemical stimuli into nerve impulses (action potentials), which are transmitted via afferent nerve fibers to the cell bodies of neurons located in the dorsal root ganglia (DRG). Ultimately, they are transmitted to higher neural centers, causing pain sensation. The generation and conduction of action potentials in neurons, in turn, depend on voltage-gated sodium channels (VGSCs) on the cell membrane. When the cell membrane depolarizes, sodium channels activate and open, causing an influx of sodium ions, further depolarizing the cell membrane and generating action potentials. Therefore, inhibiting abnormal sodium channel activity can help treat and relieve pain.

[0005] Voltage-gated sodium ion channels are widely present on the cell membranes of excitable cells such as neurons and skeletal muscle cells. They are a type of transmembrane glycoprotein complex composed of one α subunit and several β subunits. The α subunit is the functional carrier of the sodium ion channel and is composed of 1700 to 2000 amino acids. The β subunit mainly plays an auxiliary role and can modify the dynamics and voltage gating dependence of the ion channel. Sodium ion channels can be classified according to the different α subunits. At present, 9 sodium ion channel subtypes have been identified in mammals, namely Na v 1(Na v 1.1~Na v 1.9). Different subtypes show different tissue distribution and electrophysiological and pharmacological characteristics. Based on whether they can be effectively inhibited by nanomolar tetrodotoxin (TTX), sodium ion channels are divided into TTX-sensitive (TTX-S) and TTX-resistant (TTX-R). v 1.1、Na v 1.2 Na v 1.3 and Na v 1.7 is TTX-S type, the encoding gene is located on human chromosome 2q23-24, and they are expressed in large quantities in neurons. v 1.5 Na v 1.8 and Na v 1.9 is TTX-R type, and the encoding gene is located on human chromosome 3p21-24. v 1.5 is mainly present in myocardial cells, Na v 1.8, Na v 1.9 exists in the peripheral nervous system (PNS).

[0006] Na v 1.8 is an important ion channel involved in chronic pain, atrial fibrillation, and Budd-Chiari syndrome, and is a highly selective target for the treatment of pain. It has been shown to act as a carrier of sodium current, maintaining the action potential firing of neurons in the small dorsal root ganglion, and also participating in the spontaneous electrical signal firing of damaged neurons, such as driving the generation of neuropathic pain. v 1.8 Small molecule inhibitors include PF-01247324, A-803467, PF-06305591, VX-150, HRS-4800, JMKX-000623, HBW-004, and VX-548. PF-01247324, A-803467, and PF-06305591 have disadvantages such as poor selectivity, poor pharmacokinetic data, and low bioavailability.

[0007] Summary of the Invention

[0008] In the first aspect of the present invention, there is provided a compound of formula I

[0009] or a pharmaceutically acceptable salt thereof; when a chiral center exists, the compound further includes stereoisomers and racemates thereof.

[0010] In some embodiments of the present invention, the above compound is further represented by Formula IA or IB:

[0011] In the above compounds, R a1 、R a2 、R a3 Each is independently selected from hydrogen, halogen, hydroxy, C1-C5 alkyl, C1-C5 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, -N(R c3 R c4 ) m , and the alkyl, alkoxy, cycloalkyl, cycloalkoxy are optionally substituted by one or more halogen, hydroxy, cyano, C1-C5 alkyl, C1-C5 alkoxy, amino.

[0012] In some embodiments of the present invention, any two adjacent R a1 、R a2 、R a3 Connected to form a 5-7 membered ring, the 5-7 membered ring can be a saturated or unsaturated carbocyclic ring or heterocyclic ring; the heterocyclic ring optionally contains one or more N, O, S (=O) m Heteroatoms; the 5-7 membered ring may be optionally substituted by one or more halogen, hydroxy, cyano, C1-C5 alkyl, C1-C5 alkoxy, amino.

[0013] In some embodiments of the present invention, R a1 、R a2 、R a3 Each is independently selected from fluorine, chlorine, methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethoxy, difluoromethoxy, and amino.

[0014] In some embodiments, any two adjacent R a1 、R a2 、R a3 Connected to form a 5- or 6-membered carbocyclic or heterocyclic ring.

[0015] In some embodiments, the 5-membered or 6-membered heterocyclic ring contains one or two N, O, S (=O) m heteroatom.

[0016] In some specific embodiments, the 5-membered or 6-membered carbocyclic or heterocyclic ring is optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, or amino.

[0017] In the above compounds, R b1 、R b2 、R b3 、R b4 Each is independently selected from hydrogen, halogen, hydroxy, C1-C5 alkyl, C1-C5 alkoxy, and the alkyl and alkoxy groups are optionally substituted with one or more halogen, hydroxy, cyano, C1-C5 alkyl, C1-C5 alkoxy, and amino groups.

[0018] In a specific embodiment of the present invention, R b1 、R b2 、R b3 、R b4 Each is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, and ethoxy.

[0019] In some embodiments, R b1 、R b2 Each is independently selected from hydrogen, methyl, and trifluoromethyl.

[0020] In some embodiments, R b3 、R b4 Each is independently selected from hydrogen, methyl, and trifluoromethyl.

[0021] In some embodiments, R b1 、R b2 、R b3 、R b4 Any two of them are connected to form a 3-7 membered ring; the 3-7 membered ring may be a saturated or unsaturated carbocyclic ring or heterocyclic ring; the heterocyclic ring may optionally contain one or more N, O, S (=O) m Heteroatom; the 3-7 membered ring may be further optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, amino.

[0022] In some embodiments, R b1 、R b2 The 3-7 membered saturated carbon ring is connected to form a 3-7 membered ring, and the 3-7 membered ring can be optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, and amino.

[0023] In some embodiments, R b1 、R b2The three-membered ring can be connected to form a saturated three-membered carbon ring, and the three-membered ring can be optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, and amino.

[0024] In some embodiments, R b3 、R b4 The 3-7 membered rings are connected to form a saturated carbon ring, and the 3-7 membered rings can be optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, and amino groups.

[0025] In some embodiments, R b1 、R b2 With R b3 、R b4 Any two of them are connected to form a 3-7 membered ring, and the 3-7 membered ring can be optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, and amino.

[0026] In some embodiments, R b1 、R b2 With R b3 、R b4 Any two of them are connected to form a 3-7 membered saturated carbon ring, and the 3-7 membered saturated carbon ring can be optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, and amino.

[0027] In some embodiments, R b1 、R b2 With R b3 、R b4 Any two of them are connected to form a 3-6 membered saturated carbon ring, and the 3-6 membered saturated carbon ring can be optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, and amino.

[0028] In the present invention, R b1 、R b2 With R b3 、R b4 Any two connections can be R b1 With R b3 、R b1 With R b4 、R b2 With R b3 、R b2 With R b4 connect.

[0029] M1, M2 are independently selected from C, O, S(=O) m NR n , where R nOptionally selected from hydrogen, C1-C5 alkyl; in one embodiment, R n Optionally selected from hydrogen, methyl or ethyl.

[0030] In the above compounds of the present invention, ring A has the structure of A1:

[0031] Any single or double bond can be represented, provided that it does not violate the principles of chemical bonding;

[0032] X1, X2, X3, X4, X5 are each independently selected from a bond, C, N, O, C=O, S(=O) m ;

[0033] X1, X2, X3, X4, and X5 are selected from a "bond" to indicate that they are directly connected in the form of a bond, provided that this does not violate the principles of chemical bonding. For example, when X2 is selected from a bond, X1 is directly connected to X3 through a bond, and in this case, ring A is a five-membered ring;

[0034] In some embodiments of the present invention, X1, X2, X3, X4, and X5 are each independently selected from a bond, C, N, C=O, and S(=O)2;

[0035] In some embodiments of the present invention, X1, X2, X3, X4, and X5 are all selected from C atoms;

[0036] In some specific embodiments of the present invention, any of X1, X2, X3, X4, and X5 contains one or two N atoms;

[0037] In some specific embodiments of the present invention, any of X1, X2, X3, X4, and X5 contains a C=O;

[0038] In some specific embodiments of the present invention, any of X1, X2, X3, X4, and X5 contains one S(=O)2;

[0039] In some embodiments of the present invention, X1, X2, X3, X4, and X5 are arbitrarily selected from a bond, C, S, or O;

[0040] In some embodiments of the present invention, Ring A has the following structure:

[0041] In the above compounds of the present invention, ring A has a structure such as A2

[0042] in, arbitrarily represents a single bond or a double bond, provided that it does not violate the principles of chemical bonding; X1, X2, X3, and X4 have the same definitions as in Formula A1. X1, X2, X3, and X4 are selected from "bonds" to indicate direct linkage via bonds. For example, when X3 is selected from a bond, X2 is directly linked to X4 via a bond to form a five-membered ring; Y1 and Y2 can be the same or different and can be selected from carbon atoms or nitrogen atoms.

[0043] In some embodiments of the present invention, in formula A2, X1, X2, X3, and X4 are each independently selected from a bond, C, N, or C=O;

[0044] In some embodiments of the present invention, in formula A2, X1, X2, X3, and X4 are each independently selected from a bond, C, N, and O;

[0045] In some embodiments of the present invention, X1, X2, X3, and X4 in formula A2 are each independently selected from a bond, C, N, S(=O) m ;

[0046] In some embodiments of the present invention, in formula A2, X1, X2, X3, and X4 are each independently selected from C, N, and C=O;

[0047] In some embodiments of the present invention, Ring A has the following structure:

[0048] R c1 、R c2 Each is independently selected from hydrogen, halogen, cyano, hydroxy, amino, C1-C5 alkyl, C1-C5 alkoxy, -S(=O) m -R c3 R c4 、-C(=O)-NR c3 R c4 、-C(=S)-NR c3 R c4 、-N(R c3 R c4 ) m 、-P(=O) m -R c3 R c4 、-C(=N)-NR c3 R c4 、-S(=O)2NR c3 R c4 、-CH2NR c3 R c4 、-S(=O)(=NR c3 )R c4; and the C1-C5 alkyl group and the C1-C5 alkoxy group may be further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, C1-C5 alkyl group and C1-C5 alkoxy group;

[0049] R c1 、R c2 Any substitutable position on ring A is substituted, including substitution on X1, X2, X3, X4, Y1, and Y2; in some embodiments of the present invention, R c1 、R c2 Substituted on a carbon atom; In some embodiments of the present invention, R c1 、R c2 Substitution on heteroatoms.

[0050] R c3 、R c4 Each is independently selected from hydrogen, hydroxy, amino, C1-C5 alkyl, C1-C5 alkoxy, 3-7 membered ring, or R c3 、R c4 connected to form a 3-7 membered ring; the 3-7 membered ring may be a saturated or unsaturated carbocyclic ring or heterocyclic ring; the heterocyclic ring may optionally contain one or more N, O, S (=O) m Heteroatom; the 3-7 membered ring may be further optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, amino.

[0051] When R c1 、R c2 Selected from the substituent -S(=O) m -R c3 R c4 When m=2, then R c3 or R c4 None of them exists.

[0052] In some embodiments of the present invention, the compound of formula I described above is further represented by general formula II:

[0053] Among them: M1, Ring A, R a1 、R a2 、R a3 、R b1 、R b2 、R b3 、R b4 、R c1 、R c2 As defined above.

[0054] In some embodiments of the present invention, R c1 、R c2Each is independently selected from hydrogen, hydroxy, amino, fluorine, cyano, oxo, methyl, -C(=O)NH2, -C(=O)NHCH3, -C(=O)NHC2H5, -S(O)2CH3, -S(O)2NH2, -S(O)2NHCH3, -S(O)2NHCD3, -P(O)(CH3)2,

[0055] In some embodiments of the present invention, R c1 、R c2 Each is independently selected from hydrogen, fluorine, chlorine, amino, cyano, -C(=O)NH2.

[0056] In the above compounds of the present invention, m and n are arbitrarily 0, 1 or 2.

[0057] In a specific embodiment of the present invention, the specific compound of the present invention has the following structure:

[0058] In a second aspect, the present invention provides a compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof for use in the preparation of a medicament for inhibiting a voltage-gated sodium channel, wherein the voltage-gated sodium channel is Nav1.8.

[0059] In a third aspect, the present invention provides a compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof for use in the preparation of a medicament for treating, preventing or alleviating voltage-gated sodium channel-related diseases, including but not limited to pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or arrhythmia.

[0060] The pain includes: acute pain, chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, and visceral pain. Therefore, the present invention further provides a use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating, preventing, or alleviating pain.

[0061] In a fourth aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof and pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients include fillers, disintegrants, surfactants, and solubilizers.

[0062] The pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof of the present invention can be administered in various known ways, such as oral, topical, rectal, parenteral, inhalation or implantation. The pharmaceutical composition can be prepared into the form of tablets, capsules, bagged granules, dragees, powders, granules, lozenges, powder injections, liquid preparations or suppositories.

[0063] In a fifth aspect, the present invention provides a use of a pharmaceutical composition containing a compound of formula I or a pharmaceutically acceptable stereoisomer thereof in the preparation of a medicament for treating, preventing or alleviating voltage-gated sodium channel-related diseases, wherein the voltage-gated sodium channel-related diseases include but are not limited to pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or arrhythmia.

[0064] The pain includes: acute pain, chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, and visceral pain. Therefore, the present invention further provides a pharmaceutical combination containing a compound of formula I or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament for treating, preventing, or alleviating pain. DETAILED DESCRIPTION

[0065] Explanation of terms

[0066] "Halogen" or "halogen atom" includes fluorine, chlorine, bromine and iodine; in the present invention, preferred halogen is fluorine or chlorine.

[0067] "C1-C5 alkyl" refers to a straight-chain or branched alkyl group containing 1-5 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, etc.; the preferred C1-C5 alkyl group is C1-C3 alkyl, including methyl, ethyl, propyl, and isopropyl.

[0068] "C1-C5 alkoxy" refers to a straight-chain or branched alkoxy group containing 1-5 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, and tert-butoxy. Preferred C1-C5 alkoxy groups are C1-C3 alkoxy groups, including methoxy, ethoxy, propoxy, and isopropoxy. "C3-C6 cycloalkyl" refers to a cycloalkyl group containing 3-6 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The cycloalkyl group may be further substituted with one or more of the following substituents: halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, and amino.

[0069] "C3-C6 cycloalkoxy" refers to a cycloalkoxy group containing 3-6 carbon atoms, including cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, and cyclohexyloxy; the cycloalkoxy group may be further substituted with the following substituents: one or more halogens, hydroxyls, cyano groups, C1-C5 alkyl groups, C1-C5 alkoxy groups, and amino groups.

[0070] "3-7 membered ring" refers to a saturated or unsaturated ring containing 3-7 carbon atoms, such as a three-membered ring, a four-membered ring, a five-membered ring, a six-membered ring, or a seven-membered ring; in the present invention, the carbon atoms in the ring may be arbitrarily replaced by one or more C(=O), N, O, S(=O), m Substitution forms a 3-7 membered heterocyclic ring; the 3-7 membered ring may be further optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, amino, and m is 0, 1, or 2.

[0071] "5-7 membered ring" refers to a saturated or unsaturated ring containing 5-7 carbon atoms, such as a 5-membered ring, a 6-membered ring, or a 7-membered ring; in the present invention, the carbon atoms in the ring may be arbitrarily replaced by one or more N, O, S (=O) m Substitution forms a 5-7 membered heterocyclic ring; the 5-7 membered ring may be further optionally substituted by one or more halogen, hydroxyl, cyano, C1-C5 alkyl, C1-C5 alkoxy, amino, and m is 0, 1, or 2.

[0072] "Multiple" can be two, three, four or more. In the present invention, multiple halogen substitutions can be trifluoromethyl, difluoromethyl.

[0073] The alkyl, alkoxy, cycloalkyl, cycloalkoxy, 5-7 membered ring, 3-7 membered ring described in the present invention may be optionally substituted with one or more deuterium, halogen, hydroxyl, cyano, oxo, C1-C5 alkyl, C1-C5 alkoxy, or amino groups.

[0074] As used herein, in any chemical structure or formula, bold or hashed direct bonds (respectively) attached to a stereogenic center of the compound are ), such as in In the example, the relative stereochemistry of a stereogenic center is indicated with respect to the other stereogenic center to which it is connected by a bold or hashed direct bond.

[0075] As used herein, in any chemical structure or formula, a bold or hashed wedge-shaped bond (respectively, ), such as in In the examples, represents the absolute stereochemistry of a stereogenic center and the relative stereochemistry of a stereogenic center with respect to the other stereogenic center to which it is connected by a bold or hashed wedge bond.

[0076] As used herein, the prefix "rel-" when used in conjunction with a chiral compound refers to a single enantiomer of unknown absolute configuration. In compounds with the "rel-" prefix, the (R)- and (S)- designators in the chemical name reflect the relative stereochemistry of the compound, but not necessarily the absolute stereochemistry of the compound.

[0077] “Pharmaceutically acceptable salts” include, but are not limited to, acid addition salts formed between a compound of formula (I) and an inorganic acid, such as hydrochloride, hydrobromide, phosphate, sulfate, nitrate, and the like; and acid addition salts formed between a compound of formula (I) and an organic acid, such as formate, acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethanesulfonate, and benzoate.

[0078] The compounds of the present invention also include tautomers, such as tautomers of enol and keto structures, which are the same compound.

[0079] The present invention further prepares specific compounds by the following method. Unless otherwise specified, the compounds, reagents, etc. used in the examples of the present invention were purchased from qualified suppliers or synthesized with reference to methods disclosed in the prior art. The synthesis of some intermediate compounds can refer to the method described in WO2021113627A1, such as the preparation of intermediates 1a, 16a, etc. with reference to the methods of the prior art.

[0080] Example 1:

[0081] rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(3-oxoisoindolin-5-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide

[0082] To a reaction flask, rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid (1a, 100 mg, 0.28 mmol) was added, along with dichloromethane (25 mL) and 1 drop of N,N-dimethylformamide. Oxalyl chloride (72 mg, 0.56 mmol) was added dropwise under nitrogen protection and in an ice-water bath. After the addition was complete, the ice-water bath was removed, the mixture was warmed to room temperature, and stirred for 1 hour. The reaction solvent was then concentrated to remove the solvent. The residue was dissolved in dichloromethane (25 mL), and a solution of 6-aminoisoindolin-1-one (1b, 50 mg, 0.34 mmol) in dichloromethane (10 mL) was added dropwise at -10°C. After the addition was complete, the mixture was warmed to room temperature and stirred for 1 hour. The reaction mixture was quenched by adding water (25 mL). After separation, the aqueous phase was extracted twice with DCM. The organic phases were combined and washed once with water and once with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated. The desired product (102 mg, 75% yield) was obtained by column chromatography. ESI-MS m / z calc. 484.4, found 485.1 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ10.59(s,1H),8.54(s,1H),8.01(d,J=1.8Hz,1H),7.76(dd,J=8.2,1.9Hz,1H),7.50(d,J=8.2Hz,1H),7.23–7.12(m,1H),5.14 (d,J=10.4Hz,1H),4.30(s,2H),4.26(dd,J=10.4,7.6Hz,1H),3.95(d,J=1. 9Hz, 3H), 2.76 (dt, J = 14.7, 7.4Hz, 1H), 1.61 (s, 3H), 0.73 (d, J = 6.3Hz, 3H).

[0083] Example 2: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(2-oxoisoindolin-6-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide

[0084] 6-aminoisoindolin-2-one was substituted for 6-aminoisoindolin-1-one in Example 1, and a similar method to Example 1 was used to obtain Example 2. ESI-MS m / z calc. 484.4, found 485.1 (M+1) + . 1H NMR (400MHz, DMSO-d6) δ10.37(s,1H),10.32(s,1H),7.30(s,1H),7.20–7.14(m,2H),7.11–7.05(m,2H),5.08(d,J=10. 4Hz,1H),4.27–4.19(m,1H),3.95(d,J=2.0Hz,3H),3.39(s,2H),2.78–2.70(m,1H),1.58(s,3H),0.72(d,J=6.1Hz,3H).

[0085] Example 3:

[0086] Step 1: 3-Bromo-6-nitrobenzofuran-1(3H)-one (3b)

[0087] To a 100 mL reaction flask, 3a (3.0 g) and CCl₄ (30 mL) were added, followed by NBS (3.28 g) and AIBN (275 mg) with stirring. The mixture was heated to 78°C and stirred for 12 hours. TLC was used to monitor the reaction until complete conversion of the starting material. The reaction solution was cooled to room temperature and filtered through celite. The filtrate was concentrated and separated by column chromatography (EA / PE, 0% to 30%) to give 3.3 g of a yellow solid, in a 77% yield. LCMS: m / z (254 nm): 257.9 [M+H] +

[0088] Step 2: 7-nitrophthalazin-1(2H)-one (3c)

[0089] 3b (1.0 g) and 5% HCl (5 mL / mmol) were added to the reaction flask and stirred at 80°C for 3 hours. The reaction was monitored by TLC until the conversion of the starting material was complete. The reaction solution was cooled to room temperature, and N2H4·H2O (274 mg) was added. Stirring was continued at room temperature for 3 hours. The reaction was monitored by TLC until the conversion of the starting material was complete. The reaction solution was filtered and washed with water. The solid residue was separated by column chromatography to obtain 237 mg of a white solid, a 32% yield. LCMS: m / z (254 nm): 192.0 [M+H] +

[0090] Step 3: 7-aminophthalazin-1(2H)-one (3d)

[0091] 3c (200 mg), MeOH (10 mL), and THF (10 mL) were added to the reaction flask and stirred. Palladium / carbon (20 mg) was then added and the atmosphere was replaced with hydrogen three times. The mixture was stirred at room temperature for 4 hours. TLC was used to monitor the reaction until the conversion of the starting material was complete. The reaction solution was filtered through celite and the filtrate was concentrated to give 120 mg of a white solid, a yield of 71%. LCMS: m / z (254 nm): 162.0 [M+H] +

[0092] Step 4: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-4-oxa-3,4-dihydrophthalazin-6-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 3)

[0093] To a 25 mL reaction flask, 1a (30 mg), DMF (1 mL), HATU (49 mg), and DIPEA (22 mg) were added and stirred for 5 minutes. Then, 3d (17 mg) was added and stirred at room temperature for 12 hours. LCMS analysis showed near-complete conversion of the starting material. Water (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel chromatography (EA / PE, 50%) to afford 11.2 mg of a white solid, in a 26.6% yield. LCMS: m / z (254 nm): 498.1 [M+H]. + . 1 H NMR (400MHz, DMSO-d6) δ12.55(s,1H),10.71(s,1H),8.56(d,J=2.0Hz,1H),8.27(s,1H),8.08(dd,J=8.6,2.2Hz,1H),7.89(d,J=8.6Hz,1H),7.20 –7.12(m,2H),5.13(d,J=10.3Hz,1H),4.29(dd,J=10.1,7.8Hz,1H),3.95 (d,J=2.0Hz,3H),2.84–2.72(m,1H),1.62(s,3H),0.74(d,J=6.1Hz,3H).

[0094] Example 4: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(4-oxyylidene-3H-quinazolin-6-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (4)

[0095] Using 6-amino-3,4-dihydroquinazolin-4-one to replace 1b in Example 1, a similar method to Example 1 was used to obtain Example 4. ESI-MS m / z calc. 484.4, found 485.1 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ12.25–12.16(m,1H),10.60(s,1H),8.51(d,J=2.5Hz,1H) ,8.11–7.94(m,2H),7.67(d,J=8.8Hz,1H),7.28–7.15(m,2H),5.14(d,J=10.3Hz, 1H), 4.32 (dd, J=10.3, 7.6Hz, 1H), 3.99 (d, J=2.1Hz, 3H), 2.81 (t, J=7.5Hz, 1H), 1.66 (s, 3H), 0.78 (dd, J=7.4, 2.5Hz, 3H).

[0096] Example 5:

[0097] Step 1: Methyl 2-hydroxy-5-nitrobenzoate (5b)

[0098] Methanol (50 mL) and 5a (5.0 g) were added to a three-necked flask, and thionyl chloride (10 mL) was slowly added dropwise. The mixture was reacted at 65°C for 16 hours, concentrated to dryness, and extracted with water and ethyl acetate. The ethyl acetate layer was concentrated to obtain 6.0 g of a white solid, with a yield of 111%. ESI-MS m / z calc. 197.2, found 198.1 (M+1) + .

[0099] Step 2: (2-Hydroxy-5-nitrophenyl)methanehydroxyamine (5c)

[0100] Methanol (500 mL) and potassium hydroxide (21 g) were added to the reaction flask. Hydroxylamine hydrochloride (17.5 g) was added under ice-cooling and stirred for 1.5 h. The filtrate was filtered and 5b (5 g) was added. The reaction was allowed to proceed for 16 h. LCMS confirmed the reaction was complete. The methanol was removed by concentration, and the pH was adjusted to 2 with hydrochloric acid. The product was extracted with water and ethyl acetate. The ethyl acetate layer was dried and concentrated to give 4.8 g of a light yellow solid, with a yield of 96%. ESI-MS m / z calc. 198.0, found 198.9 (M+1) + .

[0101] Step 3: 5-Nitro-2,3-dihydrobenzo[d]isoxazol-3-one (5d)

[0102] THF (100 mL) and 5c (2.76 g) were added to the reaction flask. Triphenylphosphine (4.8 g) was added under nitrogen protection. After stirring in an ice bath for 20 minutes, DIAD (3.7 g) was added and the reaction was complete for 4 hours. LCMS confirmed the reaction was complete. The solvent was removed by concentration, water was added, the pH was adjusted to 13 with sodium hydroxide, and the mixture was extracted with DCM. The aqueous layer was taken, the pH was adjusted to 1 with hydrochloric acid, and the mixture was extracted with DCM. The mixture was washed with saturated brine and concentrated to give 1.6 g of a white solid, with a yield of 64%. ESI-MS m / z calc. 180.0, found 181.0 (M+1) + .

[0103] Step 4: 5-amino-2,3-dihydrobenzo[d]isoxazol-3-one (5e)

[0104] Methanol (50 mL), 5d (800 mg), and 5% palladium on carbon (200 mg) were added to the reaction flask and reacted under hydrogenation conditions for 36 h. LCMS confirmed the reaction was complete. The filtrate was filtered and concentrated to give 400 mg of a white solid, yield: 60.6%. ESI-MS m / z calc. 150.0, found 151.0 (M+1) + .

[0105] Step 5: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(3-oxyylidene-2H-benzo[d]isoxazol-5-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 5)

[0106] Replacing 1b in Example 1 with 5e, and using a method similar to Example 1, Example 5 was obtained. ESI-MS m / z calc. 486.1, found 487.1 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ11.63(s,1H),10.30(s,1H),7.58(d,J=2.0Hz,1H),7.29–7.09(m,5H),5.08(d,J= 10.4Hz,1H),4.36–4.23(m,1H),3.99(d,J=2.1Hz,3H),2.87–2.73(m,1H),1.63(s,3H),0.80–0.73(m,3H).

[0107] Example 6: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(1-oxyylidene-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (6)

[0108] Using 7-amino-1,2,3,4-tetrahydroisoquinolin-1-one to replace 1b in Example 1, a similar method to Example 1 was used to obtain Example 6. ESI-MS m / z calc. 498.2, found 499.2 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ10.34(s,1H),8.11(d,J=2.3Hz,1H),7.94(d,J=3.3Hz ,1H),7.75(dd,J=8.2,2.4Hz,1H),7.31–7.14(m,3H),5.09(d,J=10.4Hz,1H), 4.28(dd,J=10.4,7.6Hz,1H),3.99(d,J=2.1Hz,3H),3.37(td,J=6.5,2.7Hz,2 H),2.87(t,J=6.6Hz,2H),2.82–2.76(m,1H),1.64(s,3H),0.83–0.71(m,3H).

[0109] Example 8: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(1-oxyylidene-2,3-dihydro-1H-isoindol-5-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide

[0110] Using 5-amino-2,3-dihydro-1H-isoindol-1-one to replace 1b in Example 1, a similar method to Example 1 was used to obtain Example 8. ESI-MS m / z calc. 484.1, found 485.2 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ10.54(s,1H),8.45(s,1H),7.98(d,J=6.5Hz,2H),7.63(d,J=1.1Hz,2H),7.31–7.12(m,3H),5. 14(d,J=10.3Hz,1H),4.35(s,2H),3.99(d,J=2.1Hz,3H),2.93(s,2H),2.77(s,2H),1.64(s,3H),0.78(d,J=7.4Hz,3H).

[0111] Example 9:

[0112] Step 1: 6-aminophenylpropionic acid [d] isothiazol-3 (2H) -one-1,2-dioxide (9b)

[0113] 9a (650 mg) and concentrated hydrochloric acid (9 mL) were added to the reaction flask under an ice bath. Zinc powder (1.1 g) was added portionwise over approximately 30 minutes and stirring was continued at room temperature for 2 hours. LCMS analysis indicated that the starting material was nearly completely converted. Saturated sodium bicarbonate solution was added to the reaction mixture under an ice bath until weakly alkaline. The mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered to obtain 320 mg of a tan solid (approximately 70% purity), with a yield of 37.0%. LCMS: MS m / z (254 nm): 185.0 [M+H] + .

[0114] Step 2: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(1,1-dioxo-2,3-dihydrobenzo[d]isothiazol-6-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 9)

[0115] 9b was substituted for 3b in Example 3, and a method similar to Example 3 was used to obtain Example 9. LCMS: Rt: 2.625 min; MS m / z (254 nm): 521.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ10.53(s,1H),8.12(d,J=1.5Hz,1H),7.82(t,J=4.7Hz,1 H),7.77(dd,J=8.4,1.8Hz,1H),7.50(d,J=8.4Hz,1H),7.16(t,J=6.5Hz,2H),5.0 9(d,J=10.3Hz,1H),4.34(d,J=4.8Hz,2H),4.26(dd,J=10.1,7.8Hz,1H),3.95(d ,J=2.0Hz,3H),2.78(dd,J=14.7,7.4Hz,1H),1.61(s,3H),0.73(d,J=6.7Hz,3H).

[0116] Example 10: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(1,3-dioxyylidene-2,3-dihydro-1H-isoindol-5-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (10)

[0117] Using 5-amino-2H-isoindole-1,3-dione instead of 1b in Example 1, a similar method to Example 1 was used to obtain Example 10. ESI-MS m / z calc. 498.1, found 499.2 (M+1) +. 1 H NMR (400MHz, DMSO-d6) δ11.24(s,1H),10.73(s,1H),8.14(d,J=1.8Hz,1H),7.94(dd,J=8.2,1.8Hz,1H),7.77(d,J=8.2Hz,1H),7.27– 7.11(m,2H),5.11(d,J=10.1Hz,1H),4.32–4.16(m,1H),3.95(d,J=2.1Hz,3H),2.85–2.71(m,1H),1.61(s,3H),0.74(d,J=7.4Hz,3H).

[0118] Example 12: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(1,4-dioxy-2,3-dihydrobenzo[2,1-d][1,2]diazepine-6-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (12)

[0119] Using 6-amino-1,2,3,4-tetrahydrobenzo[2,1-d][1,2]diazepine-1,4-dione instead of 1b in Example 1, a similar method to Example 1 was used to obtain Example 12. ESI-MS m / z calc. 513.1, found 514.1 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ11.52(s,1H),10.76(s,0H),8.45(s,0H),8.07(s,1H),7.21(dd,J=8.6,5.0Hz,1H),5.16(d,J=10. 2Hz, 0H), 4.32 (dd, J=10.3, 7.6Hz, 1H), 3.98 (dd, J=9.9, 2.1Hz, 2H), 2.83 (q, J=7.6Hz, 0H), 1.66 (s, 2H), 0.83–0.62 (m, 2H).

[0120] Example 13:

[0121] Step 1: 5-amino-2-[amino(nitrogenylidene)methyl]benzoic acid (13b)

[0122] Compound 4-aminophthalonitrile 13a (500 mg, 3.49 mmol, 1.0 eq) was dissolved in methanol:water (3:2) (5 mL) and sodium hydroxide (139 mg, 3.49 mmol, 1.0 eq) was added. The reaction mixture was incubated at 100°C under nitrogen for 1 hour. LCMS monitored the reaction completion. The reaction mixture was cooled to room temperature and concentrated. The residue was isolated and purified by prep-HPLC (0.01% FA) to afford compound 5-amino-2-carbamoylbenzoic acid 13b (733 mg, 82% yield) as a yellow solid. LCMS: [M+H] + =180.1

[0123] Step 2: 4,7-Diamino-1,2-dihydrobenzo[2,1-d][1,2]diazepine-1-one (13c)

[0124] Compound 5-amino-2-carbamoylbenzoic acid 13b (680 mg, 3.79 mmol, 1.0 eq) was dissolved in methanol (10 mL) and hydrazine hydrate (7 mL). The reaction mixture was allowed to react at 25°C for 4 hours. LCMS monitored the reaction completion. The reaction mixture was concentrated, and the residue was extracted with water (10 mL) and ethyl acetate (10 mL x 5). The residue was then washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was filtered, and the filter residue was dried under vacuum to yield compound 4,7-diaminophthalazin-1-ol 13c (100 mg, 13% yield) as a yellow solid. LCMS: [M+H] + =177.1

[0125] Step 3: rel-(2R,3S,4S,5R)-N-(1-amino-4-oxyylidene-3H-benzo[2,1-d][1,2]diazepine-6-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 13)

[0126] Compound 1a (50 mg, 0.14 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (2 mL) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (64 mg, 0.17 mmol, 1.2 eq), N,N-diisopropylethylamine (27 mg, 0.21 mmol, 1.5 eq), and 13c (29 mg, 0.17 mmol, 1.2 eq) were added. The reaction mixture was allowed to react at 25°C for 2 hours. LCMS monitored the completion of the reaction. The reaction mixture was dissolved in water (10 mL) and extracted with ethyl acetate (10 mL x 3), then washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative separation (0.01% ammonia water) to afford compound 13 (21.41 mg, 29% yield) as a white solid. LCMS: [M+H] + =513.1. 1 H NMR (400MHz, DMSO-d6) δ11.43(s,1H),10.69(s,1H),8.49(d,J=2.0Hz,1H),8.05(dd,J=8.8,2.4Hz,1H),7.99(d,J=8.8Hz,1H),7.21-7.16(m ,2H),5.88(s,2H),5.12(d,J=10.0Hz,1H),4.30-4.25(m,1H),3.96(d,J=2.0Hz,3H),2.82-2.74(m,1H),1.62(s,3H),0.74(d,J=6.4Hz,3H). 19 F NMR (377MHz, DMSO-d6) δ-73.36 (s, 3H), -138.16 (d, J = 20.7Hz, 1H), -154.96 (d, J = 20.7Hz, 1H).

[0127] Example 16: rel-2-carbamoyl-4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamido)-1-methylpyridinium iodide

[0128] Compound 16a (40 mg, 0.08 mmol, 1.0 eq), iodomethane (1 mL), and acetonitrile (2 mL) were added sequentially to a microwave tube. The reaction mixture was incubated at 80°C under nitrogen for 16 hours. LCMS monitored the reaction completion. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.01% ammonia water) to afford compound 16 (11.06 mg, 27% yield) as a white solid. LCMS: [M] + =488.1. 1H NMR (400MHz, CDCl3) δ11.38(s,1H),9.92(s,1H),8.83(s,1H),8.69(s,1H),8.12(d,J=12.8Hz,1H),7.09-7.04(m,1H),6.87-6.85(m,1H),6.06 (s,1H),5.05(d,J=11.2Hz,1H),4.31(s,3H),4.27-4.20(m,1H),3.97(d,J=2.6Hz,3H),2.89-2.79(m,1H),0.92(s,3H),0.78(d,J=6.4Hz,3H).

[0129] Example 20:

[0130] Step 1: 4-(bis(4-methoxybenzyl)amino)-N-hydroxypicolinamide (20b)

[0131] Compound 4-(bis(4-methoxybenzyl)amino)picolinic acid 20a (800 mg, 2.1 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (10 mL), and N,N'-carbonyldiimidazole (411.32 mg, 2.5 mmol, 1.2 eq) was added and stirred at 25°C for 2 hours. Hydroxylamine hydrochloride (882.81 mg, 10.6 mmol, 5.0 eq) was then added. The reaction mixture was stirred at 25°C for 2 hours. LCMS monitored the completion of the reaction, and the reaction mixture was poured into water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried, and concentrated. The residue was separated and purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound 20b (500 mg, 60% yield) as a brown solid. LCMS: [M+H] + =394.2

[0132] Step 2: 4-amino-N-hydroxypicolinamide 3 (20c)

[0133] Compound 20b (500 mg, 1.3 mmol, 1.0 eq) was dissolved in trifluoroacetic acid (3 mL). The reaction mixture was stirred at 60°C for 4 hours. LCMS monitored the reaction completion and the reaction mixture was concentrated. The residue was dissolved in dichloromethane, ethereal hydrochloric acid (2 mL) was added, and the mixture was concentrated to afford the hydrochloride salt of compound 20c (260 mg, 93% yield) as a brown solid. LCMS: [M+H] + =154.2

[0134] Step 3: rel-4-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-trifluoromethyltetrahydrofuran-2-carboxamide)-N-hydroxypicoamide (Example 20)

[0135] Compound 1a (50 mg, 0.14 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (2 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (80.48 mg, 0.21 mmol, 1.5 eq), 20c (64.8 mg, 0.42 mmol, 3.0 eq), and N,N-diisopropylethylamine (91.2 mg, 0.7 mmol, 5.0 eq) were added sequentially. The reaction mixture was stirred at 25°C for 2 hours. LCMS monitored the reaction completion. The reaction mixture was poured into water and extracted with ethyl acetate. The organic phase was washed with brine, dried, and concentrated. The residue was purified by preparative separation (0.01% formic acid) to afford 20 (4.41 mg, 6% yield) as a white solid.

[0136] LCMS: [M+H] + =490.1, 1 H NMR(400MHz,CH3OD)δ7.89(d,J=6.9Hz,1H),7.26-7.16(m,2H),6.97-6.90(m,1H),6.79-6.64(m,1H),5.1 7(s,1H),4.33-4.27(m,1H),4.01(d,J=2.2Hz,3H),2.84-2.77(m,1H),1.64(s,3H),0.80(d,J=6.2Hz,3H).

[0137] Example 21:

[0138] Step 1: Methyl 4-(bis(4-methoxybenzyl)amino)picolinate (21a)

[0139] To a microwave oven, bis(4-methoxybenzyl)amine (4 g, 1.8 mmol, 1.0 eq), methyl 4-bromopicolinate (6.2 g, 2.4 mmol, 1.3 eq), 1,1′-[1,1′-dinaphthyl]-2,2′-diylbis[1,1-diphenyl-(ACI)phosphine] (580 mg, 0.09 mmol, 0.05 eq), palladium acetate (210 mg, 0.09 mmol, 0.05 eq), cesium carbonate (12.06 g, 3.7 mmol, 2.0 eq), and toluene (40 mL) were added sequentially and stirred at 100°C for 4 hours. The reaction was monitored by LCMS, the reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to afford 21a (3.2 g, 44% yield) as a yellow solid. LCMS: [M+H] + =393.2

[0140] Step 2: 4-(Bis(4-methoxybenzyl)amino)picolinic acid (21b)

[0141] Compound 4-(bis(4-methoxybenzyl)amino)picolinic acid methyl ester 21a (3.2 g, 8.2 mmol, 1.0 eq) was dissolved in methanol / tetrahydrofuran / water (3 / 3 / 1) (30 mL). Lithium hydroxide monohydrate (1 g, 24.6 mmol, 3.0 eq) was added and stirred at 25°C for 16 hours. The reaction was monitored by LCMS. The reaction solution was poured into water and the pH was adjusted to ~5 with 1N dilute hydrochloric acid. The solution was extracted with ethyl acetate, and the organic phase was washed with brine, dried, and concentrated to afford compound 4-(bis(4-methoxybenzyl)amino)picolinic acid 21b (2 g, 65% yield) as a yellow solid. LCMS: [M+H] + =379.1

[0142] Step 3: 4-(bis(4-methoxybenzyl)amino)-N-methoxypicolinamide (21c)

[0143] Compound 4-(bis(4-methoxybenzyl)amino)picolinic acid 21b (200 mg, 0.53 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (2 mL). N,N'-carbonyldiimidazole (102.8 mg, 0.63 mmol, 1.2 eq) was added and stirred at 25°C for 2 hours. Methoxyamine hydrochloride (221 mg, 10.6 mmol, 5.0 eq) was then added. The reaction mixture was stirred at room temperature for 2 hours. LCMS monitored the completion of the reaction. The reaction mixture was poured into water and extracted with ethyl acetate. The organic phase was washed with brine, dried, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to afford compound 4-(bis(4-methoxybenzyl)amino)-N-methoxypicolinamide 21c (140 mg, 65% yield) as a brown solid. LCMS: [M+H] + =408.1

[0144] Step 4: 4-amino-N-methoxypicolinamide (21d)

[0145] Compound 4-(bis(4-methoxybenzyl)amino)-N-methoxypicolinamide 21c (100 mg, 0.24 mmol, 1.0 eq) was dissolved in trifluoroacetic acid (2 mL). The reaction mixture was stirred at 60°C for 4 hours. LCMS monitored the reaction completion and the reaction mixture was concentrated. The residue was dissolved in dichloromethane, ethereal hydrochloric acid (2 mL) was added, and the mixture was concentrated to afford the hydrochloride salt of compound 4-amino-N-methoxypicolinamide 21d (80 mg, 78% yield) as a brown solid. LCMS: [M+H] + =168.1

[0146] Step 5: rel-4-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-trifluoromethyltetrahydrofuran-2-carboxamidopicolinamide (Example 21)

[0147] Compound 1a (50 mg, 0.14 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (2 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (80.48 mg, 0.21 mmol, 1.5 eq), 4-amino-N-methoxypicolinamide 21d (70.7 mg, 0.42 mmol, 3.0 eq), and N,N-diisopropylethylamine (91.2 mg, 0.7 mmol, 5.0 eq) were added sequentially. The reaction mixture was stirred at 25°C for 2 hours. LCMS analysis indicated that most of the starting material had reacted. The reaction mixture was poured into water and extracted with ethyl acetate. The organic phase was washed with brine, dried, and concentrated. The residue was purified by preparative separation (0.01% formic acid) to afford compound 21 (4.5 mg, 6% yield) as a white solid. LCMS: [M+H] + =504.1. 1 H NMR (400MHz, CH3OD) δ8.53-8.43(m,1H),8.23(s,1H),7.88(s,1H),7.10(d,J=7.8Hz,1H),7.02-6.93(m,1H),5.06(s ,1H),4.37-4.29(m,1H),3.99(d,J=2.2Hz,3H),3.80(s,3H),2.83-2.75(m,1H),1.65(s,3H),0.81(d,J=7.6Hz,3H).

[0148] Example 22: rel-(2R,3S,4S,5R)-N-[2-(aminosulfanylidenemethyl)pyridin-4-yl]-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide

[0149] Compound 16a (30 mg, 0.06 mmol, 1.0 eq) was dissolved in toluene (20 mL), and Lawesson's reagent (26 mg, 0.06 mmol, 1.0 eq) was added. The temperature was raised to 110°C and the reaction was allowed to react for 24 hours. After the reaction was complete, the solvent was removed by concentration and thin-layer chromatography to obtain Example 22 (15 mg, 48% yield) as a yellow solid. LCMS: [M+H] + =490.5. 1H NMR (400MHz, DMSO-d6) δ11.49(s,1H),10.21(s,1H),9.93(s,1H),8.89–8.71(m,1H),8.49(d,J=5.4Hz,1H),7.93(s,1H),7.4 6–7.02(m,3H),5.29(d,J=10.7Hz,1H),4.27(d,J=8.9Hz,1H),3.99(d,J=2.8Hz,3H),2.75(m,1H),1.64(s,3H),0.75(s,3H).

[0150] Example 24: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(6-fluoro-2-oxyylidene-1H-pyridin-4-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (24)

[0151] Using 4-amino-6-fluoro-1,2-dihydropyridin-2-one to replace 1b in Example 1, a similar method to Example 1 was used to obtain Example 24. ESI-MS m / z calc. 464.1, found 465.1 (M+1) + . 1 H NMR (400MHz, Methanol-d4) δ7.08(t,J=7.5Hz,1H),7.01–6.93(m,1H),6.83(s,1H),6.75(d,J=1.4Hz,1H),5.02(d,J=10.3 Hz,1H),4.30(dd,J=10.3,8.0Hz,1H),3.99(d,J=2.2Hz,3H),2.87–2.70(m,1H),1.63(s,3H),0.80(dd,J=7.8,2.4Hz,3H).

[0152] Example 25:

[0153] Step 1: Methyl 2-cyano-5-nitrobenzoate (25b)

[0154] To a reaction flask, 25a (3 g), cuprous cyanide (2 g), and DMF (30 mL) were added. Pd2(dba)3 (527 mg) and dppf (638 mg) were added sequentially with stirring. The atmosphere was purged with nitrogen three times and stirred at 115°C for 16 hours. The reaction mixture was cooled to room temperature, water (70 mL) was added, and the mixture was extracted with ethyl acetate (40 mL x 3). The organic phases were combined, concentrated, and separated by column chromatography (EA / PE, 0% to 15%) to obtain 2 g of a white solid in an 84.4% yield. LCMS: m / z (254 nm): 207.0 [M+H] +

[0155] Step 2: 2-Cyano-5-nitrobenzamide (25c)

[0156] To the reaction mixture was added 25a (1 g) and a 7 M ammonia methanol solution (10 mL) and stirred at room temperature for 16 hours. The reaction mixture was filtered and washed with methanol to obtain 720 mg of a pale yellow solid (77.6% yield). LCMS: m / z (254 nm): 192.0 [M+H] +

[0157] Step 3: 2-cyano-5-aminobenzamide (25d)

[0158] 25c (300 mg), MeOH (10 mL), and THF (10 mL) were added to the reaction flask and stirred until uniform. Palladium / carbon (30 mg) was added and the atmosphere was replaced with hydrogen three times. The mixture was stirred at room temperature for 6 hours. TLC was used to monitor the reaction until the conversion of the starting material was complete. The reaction solution was filtered through celite and the filtrate was concentrated to obtain 179 mg of a yellow solid, with a yield of 71%. LCMS: m / z (254 nm): 162.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ9.00(s,2H),7.58(d,1H),6.77(d,1H),6.73(dd,1H),5.99(s,2H).

[0159] Step 4: rel-(2R,3S,4S,5R)-N-(3-carbamoyl-4-cyanophenyl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 25)

[0160] By replacing 3b in Example 3 with 25d and using a method similar to Example 3, Example 25 was obtained.

[0161] 1H NMR (400MHz, DMSO) δ10.87(s,1H),7.26–7.20(m,1H),7.18(d,J=8.4Hz,1H),7.08(dd,J=17.3,9.3Hz,1H),6.85(d,J=2.0Hz,1H),6.72(dd,J=8.4,2.0H z,1H),6.39(s,2H),5.22(d,J=10.6Hz,1H),4.23(dd,J=10.5,7.5Hz,1H),3 .90(d,J=2.0Hz,3H),2.72–2.61(m,1H),1.51(s,3H),0.71(d,J=6.2Hz,3H).

[0162] Example 27: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(6-oxyylidene-1H-1,2-diazacyclohexan-3-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (27)

[0163] 6-amino-3H,2H-1,2-diazacyclohexan-3-one was used to replace 1b in Example 1, and a similar method was used to obtain Example 27. ESI-MS m / z calc. 447.1, found 448.1 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ12.79(s,1H),10.75(s,1H),7.88(d,J=10.1Hz,1H),7.28–7.11(m,2H),6.92(d,J=10.1Hz,1H), 5.14(d,J=10.4Hz,1H),4.30–4.20(m,1H),3.98(t,J=2.5Hz,3H),2.78(t,J=7.5Hz,1H),1.62(s,3H),0.80–0.68(m,2H).

[0164] Example 29: rel-(2R,3S,4S,5R)-2-({[3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl]carbonyl}amino)-1,3-thiazolin-4-carboxamide (29)

[0165] 2-amino-1,3-thiazolyl-4-carboxamide was used to replace 3b in Example 3, and a similar method to Example 3 was used to obtain Example 29. ESI-MS m / z calc. 479.1, found 480.1 (M+1) + .1 H NMR (400MHz, DMSO-d6) δ12.63(s,1H),7.86(s,1H),7.59(s,1H),7.37(s,1H),7.26–7.15(m,2H),5.25(d,J=10.5H z,1H),4.30(dd,J=10.4,7.6Hz,1H),3.98(d,J=2.2Hz,2H),2.82(t,J=7.5Hz,1H),1.64(s,2H),0.80–0.68(m,3).

[0166] Example 30: rel-(2R,3S,4S,5R)-4-({[3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl]carbonyl}amino)benzene-1,2-dicarboxamide (30)

[0167] Using 4-aminobenzene-1,2-dicarboxamide to replace 1b in Example 1, a similar method to Example 1 was used to obtain Example 30. ESI-MS m / z calc. 515.1, found 516.1 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ10.42(s,1H),7.76–7.60(m,4H),7.49(d,J=8.2Hz,1H),7.30(d,J=20.8Hz,2H),7.22–7.09(m,2H),5.07( d,J=10.4Hz,1H),4.24(dd,J=10.3,7.6Hz,1H),3.95(d,J=2.1Hz,2H),2.76(t,J=7.5Hz,1H),1.60(s,3H),0.73(d,J=7.4Hz,3H).

[0168] Example 30 was separated by chiral SFC using a Daicel CHIRALPAK IH_3 column, 3.0*150 mm, 3 μm particle size, to obtain Example 30-1 (RT=1.6 min). Specific rotation [α] 2 D 0 =35.4. Example 30-2 (RT=3.0min), specific rotation [α] 2 D 0 =-35.5.

[0169] Example 31: rel-(2R,3S,4S,5R)-5-({[3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl]carbonyl}amino)benzene-1,3-dicarboxamide

[0170] Using 5-aminobenzene-1,3-dicarboxamide to replace 1b in Example 1, a similar method to Example 1 was used to obtain Example 31. ESI-MS m / z calc. 515.1, found 516.1 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ10.50(s,1H),8.23(d,J=1.5Hz,2H),8.10(t,J=1.6Hz,1H),7.99(d,J=3.2Hz,2H),7.47(s,2H),7.26–7.20( m,2H),5.14(d,J=10.5Hz,1H),4.29(dd,J=10.5,7.6Hz,1H),3.99(d,J=2.1Hz,3H),2.93(s,1H),1.65(s,3H),0.77(d,J=7.4Hz,3H).

[0171] Example 32:

[0172] Step 1: rel-(2R,3S,4S,5R)-4-({[3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl]carbonyl}amino)pyridine-2-carboxylic acid methyl ester (32a)

[0173] 4-Aminopyridine-2-carboxylic acid methyl ester was used to replace 3a in Example 3, and a similar method to Example 3 was used to obtain intermediate 32a. ESI-MS m / z calc. 488.1, found 489.1 (M+1) + .

[0174] Step 2: rel-(2R,3S,4S,5R)-4-({[3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl]carbonyl}amino)pyridine-2-carboxylic acid (32b)

[0175] 32a (80 mg), THF (5 mL), water (5 mL), and sodium hydroxide (10 mg) were added to the reaction flask and reacted at room temperature for 2 hours. The reaction was monitored for completion by TLC. The pH was adjusted to 1 and ethyl acetate was added for extraction. The organic phase was dried and concentrated, and column chromatography afforded 32b (75 mg, 98%). ESI-MS m / z calc. 474.1, found 473.1 (M-1). + .

[0176] Step 3: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-[2-(tetrahydroisoxazol-2-ylcarbonyl)pyridin-4-yl]-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 32)

[0177] 32b (30 mg), tetrahydroisoxazole (10 mg), HATU (36 mg), diisopropylethylamine (20 mg), and DMF (1 mL) were added to the reaction flask and reacted at room temperature for 17 hours. The reaction was monitored for completion by LCMS. Water and ethyl acetate were added for extraction. The organic phase was dried and concentrated, and purified by thin-layer chromatography to afford Example 32 (20 mg, 60%). ESI-MS m / z calc. 529.1, found 530.2 (M+1) + . 1 H NMR (400MHz, DMSO-d6) δ10.74(s,1H),8.51(d,J=5.6Hz,1H),8.02(d,J=27.4Hz,1H ),7.76(s,1H),7.20(dd,J=9.7,6.5Hz,2H),5.14(d,J=10.2Hz,1H),4.29(dd,J=10. 2,7.7Hz,1H),3.98(d,J=2.2Hz,4H),3.91(d,J=14.6Hz,0H),2.85(d,J=63.6Hz,2H ), 2.81 (t, J = 7.5Hz, 1H), 2.32 (p, J = 7.0Hz, 2H), 1.64 (s, 3H), 0.77 (d, J = 7.4Hz, 3H).

[0178] Example 34:

[0179] Step 1: 2-Benzylthio-4-iodopyridine (34b)

[0180] Benzyl mercaptan (2.9 g) and THF (50 mL) were added to the reaction flask and stirred until uniform. NaH (848 mg) was added portionwise under ice-cooling. After addition, the mixture was stirred at room temperature for 1 hour. Compound 34a (5 g) was added under ice-cooling. After addition, the mixture was stirred at room temperature for 3 hours. LCMS confirmed the near-complete conversion of the starting material. Water (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (EA / PE, 0%-10%) to afford 6.6 g of a light red liquid in a 90.1% yield. LCMS: MS m / z (254 nm): 327.9 [M+H]. + .

[0181] Step 2: 4-Iodopyridine-2-sulfonyl chloride (34c)

[0182] To the reaction flask were added 34b (3 g), DCM (30 mL), and DIPEA (3.8 g). Dichlorohydantoin (6.9 g) was added portionwise in an ice bath. After addition, the mixture was warmed to room temperature and stirred for 4 hours. LCMS analysis indicated the reaction was nearly complete. Water (50 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (EA / PE, 0%-10%) to afford 1.4 g of a pale yellow solid in a 24.2% yield. LCMS: MS m / z (254 nm): 585.0 [M+H]. + .

[0183] Step 3: N,N-di(2,4-dibenzyl)-4-iodopyridine-2-sulfonamide (34d)

[0184] To a reaction flask were added 34c (800 mg), N-methylpyrrolidone (7 mL), ammonium acetate (1.06 g), copper acetylacetonate (107 mg), Ligand (115 mg), and cesium carbonate (1.34 g). The atmosphere was purged with nitrogen three times and stirred at 95°C for 16 hours. The reaction mixture was cooled to room temperature, water (20 mL) was added, and extraction was performed with ethyl acetate (20 mL x 3). The organic phases were combined, concentrated, and separated by column chromatography (EA / PE, 50%-100%) to afford 460 mg of a yellow oil in a 70.8% yield. LCMS: MS m / z (254 nm): 475.1 [M+H] + .

[0185] Step 4: rel-(2R,3S,4S,5R)-N-(2-(N,N-bis(2,4-dimethoxybenzyl)sulfonyl)pyridin-4-yl)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (34e)

[0186] 34d was used to replace 3b in Example 3, and a similar method as in Example 3 was used to obtain 34e. LCMS: MS m / z (254 nm): 810.2 [M+H] + .

[0187] Step 5: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(2-sulfonylpyridin-4-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 34)

[0188] 34e (52 mg), DCM (2 mL), and trifluoroacetic acid (146 mg) were added to the reaction flask and stirred at room temperature for 12 hours. LCMS analysis indicated that the starting material was nearly completely converted. The reaction solution was concentrated and separated by silica gel chromatography (EA / PE, 40%) to afford 24.5 mg of a white solid in a 75.2% yield. LC-MS: MS m / z (254 nm): 510.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 1 H NMR (400MHz, DMSO-d6) δ10.84(s,1H),8.57(d,J=5.4Hz,1H),8.26(d,J=1.8Hz,1H),7.81(dd,J=5.5,1.7Hz,1H),7.41(s,2H),7.23–7 .11(m,2H),5.12(d,J=10.1Hz,1H),4.36–4.15(m,1H),3.95(d,J=1.8Hz,3H),2.93–2.66(m,1H),1.61(s,3H),0.73(d,J=6.1Hz,3H).

[0189] Example 59:

[0190] Step 1: (3Z)-4-(3,4-difluoro-2-methoxyphenyl)-1,1,1-trifluoro-3-methylbut-3-en-2-one (59a)

[0191] To a reaction flask, toluene (25 mL), 3,4-difluoro-2-methoxybenzaldehyde (5.0 g, 29.0 mmol, 1.0 eq), 1,1,1-trifluorobutan-2-one (11 g, 87.2 mmol, 3.0 eq), piperidine acetate (4.2 g, 29.0 mmol, 1.0 eq), and acetic acid (0.9 g, 14.5 mmol, 0.5 eq) were added sequentially. The mixture was sealed and reacted at room temperature for two hours. The temperature was then raised to 75°C and the reaction continued for 16 hours. TLC monitored the reaction for completion. The mixture was extracted with water and ethyl acetate. The ethyl acetate layer was concentrated and separated by column chromatography (PE:EA = 20:1) to afford 59a (7.5 g, 92% yield) as a yellow liquid.

[0192] Step 2: rel-(2R,3S)-3-(3,4-difluoro-2-methoxyphenyl)-4-methyl-5-(trifluoromethyl)-2,3-dihydrofuran-2-carboxylic acid ethyl ester (59b)

[0193] Acetonitrile (25 mL), compound 59a (2.5 g, 8.9 mmol, 1.0 eq), (ethoxycarbonylmethyl)dimethylsulfonium bromide (2.6 g, 11.6 mmol, 1.3 eq), and cesium carbonate (3.8 g, 11.6 mmol, 1.3 eq) were added to a reaction flask in this order and allowed to react at room temperature for 16 hours. Completion of the reaction of compound 59a was monitored by TLC (PE:EA = 10:1). The filtrate was filtered, concentrated, and then separated on a column (PE:EA = 20:1) to yield 2.3 g of a yellow liquid (72% yield).

[0194] Step 3: rel-(2R,3S)-3-(3,4-difluoro-2-methoxyphenyl)-4-methyl-5-(trifluoromethyl)-2,3-dihydrofuran-2-carboxylic acid (59c)

[0195] Methanol (25 mL), water (25 mL), compound 59b (1.0 g, 2.7 mmol, 1.0 eq), and sodium hydroxide (0.54 g, 13.6 mmol, 5 eq) were added to the reaction flask in sequence and allowed to react at 65°C for 16 hours. LCMS monitored the reaction for completion. The mixture was concentrated to remove the methanol, and the mixture was acidified with 1N hydrochloric acid. The mixture was extracted with ethyl acetate, and the ethyl acetate layer was dried and concentrated to afford 59c (0.8 g, 86% yield) as a yellow liquid.

[0196] Step 4: rel-(2R,3S)-4-({[3-(3,4-difluoro-2-methoxyphenyl)-4-methyl-5-(trifluoromethyl)-2,3-dihydrofuran-2-yl]carbonyl}amino)pyridine-2-carboxamide (59d)

[0197] To the reaction flask were added DMF (20 mL), 59c (0.8 g, 2.3 mmol, 1.0 eq), HATU (1.4 g, 3.5 mmol, 1.5 eq), triethylamine (0.7 g, 4.7 mmol, 2.0 eq), and 4-aminopyridine-2-carboxamide (0.5 g, 3.5 mmol, 1.5 eq). The reaction was allowed to react at room temperature for 16 hours. TLC monitored the reaction for completion. The mixture was extracted with water and ethyl acetate. The ethyl acetate layer was concentrated and separated by column chromatography (PE:EA = 3:1 → 1:2) to afford 59d (0.4 g, 40% yield) as a gray solid. MS: [M+H] + =458. 1 H NMR (400MHz, DMSO-d6) δ10.77(s,1H),8.56(d,J=5.5Hz,1H),8.33(d,J=2.1Hz,1H),8.11(s,1H),7.86(dd,J=5.6,2.3Hz,1H),7.66(s,1H),7.31–7. 21(m,1H),7.10(td,J=6.9,6.5,3.1Hz,1H),5.13(d,J=6.2Hz,1H),4.73( s,1H),3.94(d,J=1.9Hz,3H),1.68(d,J=2.8Hz,3H),0.88(d,J=6.9Hz,1H)

[0198] Step 5: rel-(2R,3S)-4-({[4,5-dichloro-3-(3,4-difluoro-2-methoxyphenyl)-3a-methyl-5a-(trifluoromethyl)hexahydrocyclobutane[2,1-b]furan-2-yl]carbonyl}amino)pyridine-2-carboxamide (59e)

[0199] To a quartz reaction flask, DCE (500 mL), 59d (500 mg, 1.1 mmol, 1.0 eq), and 1,2-dichloroethylene (2 mL) were added sequentially. The reaction was irradiated at 275 nm for 3 weeks. Column chromatography was used to recover 75 mg of the starting material and 20 mg of the product as a white solid, yielding 3.4%. MS: [M+H] + =554. 1 H NMR (400MHz, Methanol-d4) δ8.53(d,J=5.5Hz,1H),8.31(d,J=2.1Hz,1H),7.93(dd,J=5.5,2.2Hz,1H),7.12–7.05(m ,2H),5.41(d,J=6.0Hz,1H),4.69(q,J=7.7Hz,2H),4.61(d,J=6.0Hz,1H),4.01(d,J=2.4Hz,3H),0.95–0.93(m,3H).

[0200] Step 6: rel-(2R,3S)-4-({[3-(3,4-difluoro-2-methoxyphenyl)-3a-methyl-5a-(trifluoromethyl)hexahydrocyclobutane[2,1-b]furan-2-yl]carbonyl}amino)pyridine-2-carboxamide (59)

[0201] Toluene (15 mL), 59e (10 mg, 0.02 mmol, 1.0 eq), tributyltin hydride (52 mg, 0.2 mmol, 10 eq), and AIBN (32 mg, 0.2 mmol, 10 eq) were added to the reaction flask in sequence. The flask was sealed and reacted at 100°C for 36 hours. LCMS monitored the reaction for completion. Compound 59 (3.4 mg, 40% yield) was isolated by thin-layer chromatography as a white solid. MS: [M+H] + =486. 1 H NMR(400MHz,Chloroform-d)δ8.94(s,1H),8.50(d,J=5.4Hz,1H),8.26(s,1H),8.09(s,1H),6.99–6.88(m,1H),5.68(s,1H),5.03(s,1H ), 4.18 (s, 1H), 3.99 (d, J = 2.3Hz, 2H), 2.56 (dd, J = 17.3, 6.7Hz, 1H), 2.15 (t, J = 13.1Hz, 1H), 1.92 (dd, J = 14.5, 6.3Hz, 1H), 0.90 (s, 2H).

[0202] Example 79: rel-(2R,3S,4S,5)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)-N-(1,1,3-trioxylidene-2,3-dihydro-1λ6-benzo[d][1,2]thiazolin-6-yl)tetrahydrofuran-2-carboxamide (79)

[0203] Using a similar method to Example 1, 1b in Example 1 was replaced with 6-amino-2,3-dihydro-1λ6-benzo[d][1,2]thiazolin-1,1,3-trione to obtain Example 79. ESI-MS m / z calc. 534.5, found 533.5 (M-1) - . 1H NMR (400MHz, DMSO-d6) δ10.59(s,1H),7.97(d,J=1.8Hz,1H),7.72(dd,J=8.2,1.8Hz,1H),7.52(d,J=8.2Hz,1H),7.17(dd,J=8.5,5.2Hz, 2H),5.10(d,J=10.2Hz,1H),4.26(dd,J=10.2,7.6Hz,1H),3.95(d,J=2.1Hz,3H),2.77(p,J=7.5Hz,1H),1.61(s,3H),0.76–0.60(m,3H).

[0204] Example 80:

[0205] Step 1: 2-Bromo-3-fluoro-5-nitrobenzoic acid (80a)

[0206] The compound 2-bromo-3-fluorobenzoic acid (5g, 22.8mmol, 1.0eq) was dissolved in concentrated sulfuric acid (15mL) and fuming nitric acid (1mL) was added at 0°C. The reaction mixture was stirred at 25°C for 4 hours. The reaction was monitored by LCMS to be complete. The reaction solution was slowly poured into ice water and extracted with dichloromethane (50mL x 3). The organic phase was collected. The organic phase was washed with saturated brine (50mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified using C18 column chromatography (0.1% FA / acetonitrile = 1 / 4) to obtain the compound 2-bromo-3-fluoro-5-nitrobenzoic acid 2 (800mg, 13%) as a yellow solid. LCMS: [M+H] + =263.9.

[0207] Step 2: Methyl 2-bromo-3-fluoro-5-nitrobenzoate (80b)

[0208] Compound 2-bromo-3-fluoro-5-nitrobenzoic acid 80a (800 mg, 3.03 mmol, 1.0 eq) was dissolved in methanol (5 mL) and thionyl chloride (1 mL) was added. The reaction mixture was stirred at 80°C for 6 hours. LCMS monitored the reaction completion. The reaction solution was filtered to obtain a filtrate. The filtrate was concentrated to obtain compound methyl 2-bromo-3-fluoro-5-nitrobenzoate 80b (800 mg, 95%) as a yellow solid. LCMS: [M+H] + =277.9.

[0209] Step 3: Dimethyl 3-fluoro-5-nitrobenzoate (80c)

[0210] Methyl 2-bromo-3-fluoro-5-nitrobenzoate 80b (400 mg, 1.43 mmol, 1.0 eq) was dissolved in methanol (10 mL), and Pd(dppf)Cl2 (32 mg, 0.143 mmol, 0.1 eq) and Et3N (437 mg, 4.32 mmol, 3.0 eq) were added. The reaction mixture was stirred at 80°C for 16 hours in the presence of carbon monoxide (0.1 MPa). The reaction mixture was concentrated to obtain a residue, which was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1) to obtain dimethyl 3-fluoro-5-nitrobenzoate 80c (40 mg, 11%) as a brown oil. LCMS: [M+H]+ = 258.1.

[0211] Step 4: 3-Fluoro-5-nitroammonium phthalate (80d)

[0212] Compound 3-fluoro-5-nitrobenzoic acid dimethyl ester 80c (40 mg, 0.155 mmol, 1.0 eq) was dissolved in ammonia methanol (5 mL). The reaction was stirred at 25°C for 16 hours. The reaction solution was concentrated to a residue, which was washed with dichloromethane and filtered to obtain the solid compound 3-fluoro-5-nitroammonium phthalate 80d (20 mg, 57%) as a white solid. LCMS: [M+H] = 228.1.

[0213] Step 5: 3-Fluoro-5-aminophthalate ammonium (80e)

[0214] Compound 3-fluoro-5-nitroammonium phthalate 80d (20 mg, 0.088 mmol, 1.0 eq) was dissolved in methanol (5 mL). The reaction mixture was stirred at 25°C for 1 hour in the presence of hydrogen. The reaction mixture was filtered, and the filtrate was collected and concentrated to afford compound 3-fluoro-5-aminoammonium phthalate 80e (13 mg, 75%) as a yellow solid. LCMS: [M+H]+ = 198.1.

[0215] Step 6: rel-5-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide)-3-fluorophthalamide (Example 80)

[0216] Compound 1a (28 mg, 0.079 mmol, 1.2 eq) was dissolved in DMF (3 mL), and 3-fluoro-5-aminophthalammonium (13 mg, 0.066 mmol, 1.0 eq) 80e, HATU (30 mg, 0.079 mmol, 1.2 eq), and DIEA (10 mg, 0.079 mmol, 1.2 eq) were added. The reaction was stirred at 25°C for 1 hour. LCMS monitored the reaction completion. The reaction was purified by pre-HPLC (0.1% FA) to afford Example 80 (2.9 mg, 5%) as a white solid. LCMS: [M+H] + =534.2.1H NMR(400MHz,CD3OD)δ7.72(dd,J=2.0,2.0Hz,1H),7.63-7.61(m,1H),7.15-7.08(m,1H),7.01-6.94(m,1H),5.06 (d,J=10.4Hz,1H),4.33-4.28(m,1H),3.99(d,J=2.4Hz,3H),2.85-2.71(m,1H),1.65(s,3H),0.83-0.80(m,3H).

[0217] Example 81:

[0218] Step 1: 2-Fluoro-5-nitrobenzenesulfonamide (81b)

[0219] Compound p-fluoronitrobenzene 81a (2.0 g, 14.2 mmol, 1.0 eq) was dissolved in chlorosulfonic acid (10 mL). The reaction mixture was stirred at 110°C for 24 hours, then cooled to room temperature. The reaction mixture was slowly poured into an ice bath. After the ice had completely melted, the mixture was extracted with ethyl acetate (50 mL x 3), and the organic phase was collected. The organic phase was washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was dissolved in ethyl acetate (60 mL), and aqueous ammonia (60 mL) was slowly added at 0°C. The reaction mixture was stirred at 25°C for 16 hours. After completion of the reaction as monitored by TLC, the reaction mixture was poured into water and extracted with ethyl acetate (50 mL x 3). The organic phase was collected. The organic phase was washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 3) to give compound 2-fluoro-5-nitrobenzenesulfonamide 81b (400 mg, 13% yield) as a yellow solid. 1 H NMR (400MHz, DMSO) δ8.56-8.53(m,2H),8.06(s,2H),7.86-7.65(m,1H).

[0220] Step 2: 5-Amino-2-fluorobenzenesulfonamide (81c)

[0221] Compound 2-fluoro-5-nitrobenzenesulfonamide 81b (200 mg, 0.90 mmol, 1.0 eq) was dissolved in methanol (5 mL) and wet palladium on carbon (193 mg, 1.80 mmol, 2.0 eq) was added. The reaction mixture was stirred at 25°C in the presence of hydrogen for 1 hour. LCMS monitored the reaction completion. The reaction mixture was filtered to obtain a filtrate. The filtrate was concentrated to obtain compound 5-amino-2-fluorobenzenesulfonamide 3 (160 mg, 92% yield) as a black solid. LCMS: [M+H] + =191.1

[0222] Step 3: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(4-fluoro-3-sulfonylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 81)

[0223] Compound (3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxylic acid 1a (50 mg, 0.14 mmol, 1.0 eq) was dissolved in dichloromethane (3 mL), and compound 5-amino-2-fluorobenzenesulfonamide 81c (32 mg, 0.17 mmol, 1.2 eq), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (64 mg, 0.17 mmol, 1.2 eq), and N,N-diisopropylethylamine (22 mg, 0.17 mmol, 1.2 eq) were added. The reaction mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated to obtain a residue, which was purified by preparative separation (0.1% formic acid) to afford compound (2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(4-fluoro-3-sulfonylphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide HL-1127 (2.3 mg, 3% yield) as a white solid. LCMS: [M+H]+ = 527.1. 1H NMR (400MHz, DMSO) δ10.61(s,1H),8.57(s,1H),8.23-8.21(m,1H),7.93-7.86(m,1H),7.72(s,1H),7.46-7.39(m,1H),7.29-7.18 (m,2H),5.13(d,J=10.4Hz,1H),4.35-4.25(m,1H),4.01(d,J=2.4Hz,3H),2.85-2.79(m,1H),1.66(s,3H),0.79(d,J=5.6Hz,3H).

[0224] Example 82

[0225] Step 1: 2-(Benzylthio)-4-bromopyridine (82b)

[0226] Compound phenylmethylmercaptan 82a (2.0 g, 16.1 mmol, 1.0 eq) was dissolved in anhydrous tetrahydrofuran (30 mL) and sodium hydroxide (640 mg, 16.1 mmol, 1.0 eq) was added at 0°C under nitrogen. The reaction mixture was stirred at 0°C for 30 minutes. At the same temperature, a solution of 4-bromo-2-fluoropyridine (2.8 g, 16.1 mmol, 1.0 eq) in anhydrous tetrahydrofuran (10 mL) was added dropwise, and the mixture was stirred at 0°C for 1.5 hours. LCMS confirmed the completion of the reaction. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 3). The mixture was then washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified on a silica gel column (petroleum ether / ethyl acetate = 50 / 1) to afford compound 2-(benzylthio)-4-bromopyridine 82b (4.3 g, 95% yield) as a pink oil. LCMS: [M+H] + =280.0

[0227] Step 2: 4-Bromopyridine-2-sulfonyl chloride (82c)

[0228] Compound 2-(Benzylthio)-4-bromopyridine 82b (4.3 g, 15.3 mmol, 1.0 eq) was dissolved in 80 mL of dichloromethane:acetic acid:water (7:1:2) and 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione (1.1 g, 7.2 mmol, 0.7 eq) was added. The reaction mixture was allowed to react at 25°C under nitrogen for 16 hours. TLC confirmed the completion of the reaction. Water (20 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (20 mL x 3). The mixture was then washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, diluted with dichloromethane, filtered, and the filtrate was spin-dried to afford crude 4-bromopyridine-2-sulfonyl chloride 5 (4.5 g, 92% yield) as a yellow oil.

[0229] Step 3: 4-Bromopyridine-2-sulfonamide (82d)

[0230] Aqueous ammonia (10 mL) was added to 4-bromopyridine-2-sulfonyl chloride 82c (3.0 g, 9.4 mmol, 1.0 eq). The reaction mixture was allowed to react at 25°C for 1 hour. LCMS confirmed the complete reaction. The reaction mixture was concentrated, and the residue was purified on a silica gel column (petroleum ether / ethyl acetate = 1 / 1) to afford 4-bromopyridine-2-sulfonamide 82d (1.7 g, 77% yield) as a gray solid. LCMS: [M+H] + =238.9

[0231] Step 4: tert-Butyl ((4-bromopyridin-2-yl)sulfonyl)carbamate (82e)

[0232] Compound 4-bromopyridine-2-sulfonamide 82d (500 mg, 2.1 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and triethylamine (213 mg, 2.1 mmol, 1.0 eq), 4-dimethylaminopyridine (13 mg, 0.10 mmol, 0.05 eq), and di-tert-butyl dicarbonate (483 mg, 2.2 mmol, 1.05 eq) were added. The reaction mixture was allowed to react at 25°C for 1 hour. LCMS monitored the reaction completion of the starting material. The reaction mixture was concentrated, and the residue was purified on a silica gel column (dichloromethane / methanol = 10 / 1) to afford compound tert-butyl ((4-bromopyridin-2-yl)sulfonyl)carbamate 82e (611 mg, 85% yield) as a yellow oil. LCMS: [M+Na] + =359.0

[0233] Step 5: tert-Butyl ((4-bromopyridin-2-yl)sulfonyl)(methyl-d3)carbamate (82f)

[0234] Compound tert-butyl ((4-bromopyridin-2-yl)sulfonyl)carbamate 82e (200 mg, 0.59 mmol, 1.0 eq) was dissolved in anhydrous N,N-dimethylformamide (5 mL), and potassium carbonate (123 mg, 0.88 mmol, 1.5 eq) and deuterated iodomethane (94 mg, 0.65 mmol, 1.1 eq) were added. The reaction mixture was allowed to react at 60°C for 2 hours. LCMS confirmed the completion of the reaction. Water (10 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (10 mL x 3). The mixture was then washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified on a silica gel column (petroleum ether / ethyl acetate = 10 / 1) to afford 82f (130 mg, 62% yield) as a white solid. LCMS: [M+Na] + =376.0

[0235] Step 6: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (82g)

[0236] Ammonium chloride was used to replace 1b in Example 1, and a similar method was used to obtain intermediate 82g. LCMS: [M+H] + =354.3.

[0237] Step 7: Tert-butyl rel-((4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamido)pyridin-2-yl)sulfonyl)(methyl-d3)carbamate (82h)

[0238] Compound 82f (70 mg, 0.20 mmol, 1.0 eq) was dissolved in dioxane (5 mL), and compound 82g (139 mg, 0.24 mmol, 1.2 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (23 mg, 0.04 mmol, 0.1 eq), cesium carbonate (128 mg, 0.39 mmol, 2.0 eq), and palladium acetate (3 mg, 0.02 mmol, 0.1 eq) were added. The reaction mixture was incubated at 105°C under nitrogen for 16 hours. LCMS analysis confirmed the completion of the reaction. The reaction mixture was concentrated, and the residue was purified on a silica gel column (petroleum ether / ethyl acetate = 5 / 1) to afford 82h (65 mg, 52% yield) as a yellow oil. LCMS: [M+H] + =627.2

[0239] Step 8: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(2-(N-(methyl-d3)aminosulfonyl)pyridin-4-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (82h)

[0240] Step 8: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(2-(N-(methyl-d3)aminosulfonyl)pyridin-4-yl)-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide

[0241] 82h (50 mg, 0.08 mmol, 1.0 eq) was dissolved in dichloromethane (5 mL) and p-toluenesulfonic acid (13.72 mg, 0.08 mmol, 1.0 eq) was added. The reaction mixture was allowed to react at 25°C for 16 hours. LCMS confirmed the complete reaction. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.05% NH3) to afford Example 82 (10.0 mg, 24% yield) as an off-white solid. LCMS: [M+H] + =527.1 1 H NMR (400MHz, CH3OD) δ8.54(d,J=5.6Hz,1H),8.30(d,J=2.0Hz,1H),7.86(dd,J=5.6,2.0Hz,1H),7.14-7.09(m,1H),7.02-6.94(m,1H) ,5.08(d,J=10.4Hz,1H),4.32(dd,J=10.4,8.4Hz,1H),3.99(d,J=2.4Hz,3H),2.80(p,J=7.6Hz,1H),1.65(s,3H),0.83-0.79(m,3H).

[0242] Example 83:

[0243] Step 1: tert-Butyl ((4-bromopyridin-2-yl)sulfonyl)(ethyl)carbamate (83a)

[0244] Compound tert-butyl ((4-bromopyridin-2-yl)sulfonyl)carbamate 82e (200 mg, 0.59 mmol, 1.0 eq) was dissolved in anhydrous N,N-dimethylformamide (5 mL), and potassium carbonate (123 mg, 0.88 mmol, 1.5 eq) and iodoethane (101 mg, 0.65 mmol, 1.1 eq) were added. The reaction mixture was allowed to react at 60°C for 2 hours. LCMS confirmed the completion of the reaction. Water (10 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (10 mL x 3). The mixture was then washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified on a silica gel column (petroleum ether / ethyl acetate = 10 / 1) to afford compound tert-butyl ((4-bromopyridin-2-yl)sulfonyl)(ethyl)carbamate 83a (130 mg, 60% yield) as a yellow oil. LCMS: [M+Na] + =387.0

[0245] Step 2: Tert-butyl rel-((4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamido)pyridin-2-yl)sulfonyl)(ethyl)carbamate (83b)

[0246] Compound 83a (130 mg, 0.35 mmol, 1.0 eq) was dissolved in dioxane (5 mL), and 82 g (197 mg, 0.39 mmol, 1.2 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (41 mg, 0.07 mmol, 0.2 eq), cesium carbonate (231 mg, 0.71 mmol, 2.0 eq), and palladium acetate (6 mg, 0.03 mmol, 0.1 eq) were added. The reaction mixture was incubated at 105°C under nitrogen for 16 hours. LCMS monitored the reaction completion of the starting material. The reaction mixture was concentrated, and the residue was purified on a silica gel column (petroleum ether / ethyl acetate = 4 / 1) to afford 83b (100 mg, 44% yield) as a yellow oil. LCMS: [M+H] + =638.2

[0247] Step 3: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(2-(N-ethylaminosulfonyl)pyridin-4-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 83)

[0248] Compound 83b (100 mg, 0.16 mmol, 1.0 eq) was dissolved in hydrochloric acid / dioxane (4 M, 30 mL). The reaction mixture was incubated at 25°C for 2 hours. LCMS confirmed the complete reaction. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.01% FA) to afford Example 83 (39.5 mg, 47% yield) as a white solid. LCMS: [M+H] + =538.1

[0249] 1 H NMR (400MHz, DMSO) δ10.88(s,1H),8.59(d,J=5.2Hz,1H),8.27(d,J=1.6Hz,1H),7.91-7.75(m,2H),7.18-7.15(m,2H),5.13(d,J=10.0Hz,1H ),4.28-4.23(m,1H),3.95(d,J=2.4Hz,3H),2.97-2.86(m,2H),2.80-2.75(m,1H),1.61(s,3H),0.97(t,J=7.2Hz,3H),0.73(d,J=6.0Hz,3H).

[0250] Example 84:

[0251] Step 1: 4-Bromo-N-(2,2,2-trifluoroethyl)pyridine-2-sulfonamide (84b)

[0252] Compound 2,2,2-trifluoroethane-1-amine (1.2 g, 11.7 mmol, 3.0 eq) was added to compound 4-bromopyridine-2-sulfonyl chloride 84a (1.0 g, 3.9 mmol, 1.0 eq). The reaction mixture was allowed to react at 25°C for 1 hour. LCMS monitored the reaction completion of the starting material. The reaction mixture was concentrated, and the residue was purified on a silica gel column (petroleum ether / ethyl acetate = 10 / 1) to afford compound 4-bromo-N-(2,2,2-trifluoroethyl)pyridine-2-sulfonamide 84b (700 mg, 56% yield) as a white solid. LCMS: [M+H] + =318.9

[0253] Step 2: tert-Butyl ((4-bromopyridin-2-yl)sulfonyl)(2,2,2-trifluoroethyl)carbamate (84c)

[0254] Compound 4-bromo-N-(2,2,2-trifluoroethyl)pyridine-2-sulfonamide 84b (700 mg, 2.2 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and potassium carbonate (604 mg, 4.4 mmol, 2.0 eq), 4-dimethylaminopyridine (27 mg, 0.22 mmol, 0.1 eq), and di-tert-butyl dicarbonate (573 mg, 2.6 mmol, 1.2 eq) were added. The reaction mixture was allowed to react at 25°C for 1 hour. LCMS analysis confirmed the completion of the reaction. The reaction mixture was concentrated, and the residue was purified on a silica gel column (petroleum ether / ethyl acetate = 10 / 1) to afford tert-butyl ((4-bromopyridin-2-yl)sulfonyl)(2,2,2-trifluoroethyl)carbamate 84c (700 mg, 76% yield) as a yellow oil. LCMS: [M+Na] + =441.0

[0255] Step 3: Tert-butyl rel-((4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamido)pyridin-2-yl)sulfonyl)(2,2,2-trifluoroethyl)carbamate (84d)

[0256] Compound 84c (100 mg, 0.24 mmol, 1.0 eq) was dissolved in dioxane (5 mL), and compound 82g (154 mg, 0.26 mmol, 1.1 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (27 mg, 0.048 mmol, 0.2 eq), cesium carbonate (155 mg, 0.48 mmol, 2.0 eq), and palladium acetate (4 mg, 0.024 mmol, 0.1 eq) were added. The reaction mixture was incubated at 105°C under nitrogen for 16 hours. LCMS monitored the reaction completion of the starting material. The reaction mixture was concentrated, and the residue was purified on a silica gel column (dichloromethane / methanol = 10 / 1) to afford compound 84d (80 mg, 48% yield) as a yellow oil. LCMS: [M+H] + =692.1

[0257] Step 4: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-N-(2-(N-(2,2,2-trifluoroethyl)aminosulfonyl)pyridin-4-yl)-5-trifluoromethyltetrahydrofuran-2-carboxamide (Example 84)

[0258] Compound 84d (80 mg, 0.11 mmol, 1.0 eq) was dissolved in hydrochloric acid / dioxane (4 M, 5 mL). The reaction mixture was incubated at 25°C for 4 hours. LCMS confirmed the complete reaction. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.1% FA) to afford Example 84 (15.4 mg, 22% yield) as a white solid. LCMS: [M+H] + =592.1. 1 H NMR (400MHz, DMSO-d6) δ10.88(s,1H),8.84(t,J=6.8Hz,1H),8.59(d,J=5.2Hz,1H),8.29(d,J=2.0Hz,1H),7.87-7.84(m,1H),7.20-7.14(m,2H ),5.13(d,J=10.4Hz,1H),4.28-4.23(m,1H),3.95(d,J=2.24Hz,3H),3. 84-3.75(m,2H),2.82-2.72(m,1H),1.61(s,3H),0.73(d,J=6.0Hz,3H).

[0259] Example 85: Synthesis of Compound 85

[0260] Step 1: rel-(2R,3S)-3-(3,4-difluoro-2-methoxyphenyl)-4-methyl-5-(trifluoromethyl)-2,3-dihydrofuran-2-carboxamide (85a)

[0261] Compound 59b (5 g, 13.6 mmol, 1.0 eq) was dissolved in ammonia / methanol (7 M, 15 mL). The reaction mixture was incubated at 80°C for 16 hours. LCMS confirmed the completion of the reaction. The reaction mixture was concentrated, and the residue was purified on a silica gel column (dichloromethane / methanol = 20 / 1) to afford compound 85a (3.8 g, 83% yield) as a white solid. LCMS: [M+H] + =338.0

[0262] Step 2: rel-(1R,3R,4R,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-(trifluoromethyl)-6-(trimethylsilyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide (85b)

[0263] Compound 85a (2.0 g, 5.9 mmol, 1.0 eq) was dissolved in dichloroethane (50 mL), and trimethyl(vinyl)silane (11.8 g, 11.8 mmol, 20.0 eq) was added. The reaction mixture was irradiated with a mercury lamp at 25°C for 16 hours. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.01% FA / ACN = 1 / 1) to afford compound 85b (600 mg, 23% yield) as a yellow oil. LCMS: [M+H] + =438.2

[0264] Step 3: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (85c)

[0265] Compound 85b (500 mg, 3.0 mmol, 1.0 eq) was dissolved in dimethyl sulfoxide (20 mL), and tetrabutylammonium fluoride trihydrate (6.4 g, 22.8 mmol, 20 eq) was added. The reaction mixture was allowed to react at 100°C for 16 hours. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.01% FA / ACN = 3 / 2) to afford compound 85c (170 mg, 40% yield) as a yellow oil. LCMS: [M+H] + =366.1Step 4: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxylic acid (85d)

[0266] Compound 85c (170 mg, 0.387 mmol, 1.0 eq) was dissolved in ethanol / water (3 mL + 1 mL) and potassium hydroxide (217 mg, 3.87 mmol, 10 eq) was added. The reaction mixture was reacted at 100°C for 4 hours. LCMS monitored the reaction completion. 1 M dilute hydrochloric acid was added to the reaction mixture to adjust the pH to 5-6. The mixture was extracted with ethyl acetate (10 mL x 3) and the organic phase was collected. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain compound 85d (100 mg, 70% yield) as a yellow oil. LCMS: [M+H] + =367.1

[0267] Step 5: rel-(1R,3R,4S,5R)-N-(3-carbamoyl-4-fluorophenyl)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 85)

[0268] Compound 85d (50 mg, 0.14 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and 5-amino-2-fluorobenzamide (25 mg, 0.16 mmol, 1.2 eq), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (62 mg, 0.16 mmol, 1.2 eq), and N,N-diisopropylethylamine (21 mg, 0.16 mmol, 1.2 eq) were added. The reaction mixture was stirred at 25°C for 2 hours. LCMS monitored the reaction completion. The reaction mixture was concentrated to obtain a residue. The residue was purified by preparative separation (0.01% FA) to obtain Example 85 (7.5 mg, 9% yield) as a white solid. LCMS: [M+H] + =503.1. 1 H NMR (400MHz, CD3OD) δ7.91-7.89(m,1H),7.72-7.67(m,1H),7.11-7.06(m,1H),7.03-6.95(m,1H),6.93-6.84(m,1H),4.96(d,J=7.6Hz,1H),4. 22(d,J=7.6Hz,1H),3.88(d,J=2.0Hz,3H),2.42-2.34(m,1H),2.33-2. 25(m,1H),2.16-2.09(m,1H),1.83-1.75(m,1H),0.81(d,J=1.2Hz,3H).

[0269] Example 85 was separated by chiral SFC using a Daicel CHIRALPAK IH_3 column, 3.0*150 mm, 3 μm particle size, to obtain Example 85-1 (RT=1.4 min) and Example 85-2 (RT=2.0 min).

[0270] Example 86: rel-4-((1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamido)phthalamide (86)

[0271] Example 86 was prepared by a method similar to Step 5 in Example 85. LCMS: [M+H] + =528.1. 1 H NMR (400MHz, MeOD) δ7.89(s,1H),7.80(d,J=8.4Hz,1H),7.63(d,J=8.4Hz,1H),7.05(dd,J=25.2,18.0Hz,2H),5.10(d,J=8.0H z,1H),4.36(d,J=8.0Hz,1H),4.07-3.92(m,3H),2.68(s,1H),2.46-2.17(m,2H),1.98-1.80(m,1H),1.32(s,1H),0.93(s,3H).

[0272] Example 87:

[0273] Step 1: rel-(1R,3R,4S,5R)-2-(2-(3,4-dimethoxybenzyl)aminosulfonyl)pyridin-4-yl)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (87a)

[0274] Compound 85d (60 mg, 0.16 mmol, 1.0 eq) was dissolved in anhydrous pyridine (3 mL), and 4-amino-N,N-bis(3,4-dimethoxybenzyl)pyridine-2-sulfonamide 34e (78 mg, 0.16 mmol, 1.0 eq) and phosphorus oxychloride (100 mg, 0.66 mmol, 4.0 eq) were added. The reaction mixture was incubated at 0°C for 1.5 hours. LCMS monitoring confirmed the completion of the reaction. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The mixture was then washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated to afford compound 87a (120 mg, 89% yield) as a yellow oil.

[0275] Step 2: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-N-(2-aminosulfonylpyridin-4-yl)-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 87)

[0276] Compound 87a (120 mg, 0.15 mmol, 1.0 eq) was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (5 mL) was added. The reaction mixture was allowed to react at 25°C for 4 hours. LCMS confirmed the completion of the reaction. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.05% FA) to afford Example 87 (17.2 mg, 23% yield) as a white solid. LCMS: [M+H] + =522.1. 1 H NMR (400MHz, DMSO-d6) δ10.89(s,1H),8.59(d,J=5.6Hz,1H),8.32(d,J=2.0Hz,1H),7.90-7.88(m,1H),7.44(s,2H),7.23-7.15(m,1H),7.12-7.07 (m,1H),5.16(d,J=8.0Hz,1H),4.23(d,J=8.0Hz,1H),3.93(d,J=2.0Hz,3 H),2.44-2.35(m,2H),2.18-2.10(m,1H),1.87-1.80(m,1H),0.82(s,3H).

[0277] Example 88: Synthesis of Compound 88

[0278] Step 1: Compound ((4-bromopyridin-2-yl)sulfonyl)(methyl)carbamic acid tert-butyl ester (88a)

[0279] Compound tert-butyl ((4-bromopyridin-2-yl)sulfonyl)carbamate 82e (100 mg, 0.30 mmol, 1.0 eq) was dissolved in anhydrous tetrahydrofuran (5 mL), and potassium carbonate (82 mg, 0.59 mmol, 2.0 eq) and iodomethane (50 mg, 0.35 mmol, 1.2 eq) were added. The reaction mixture was allowed to react at 60°C for 2 hours. LCMS confirmed the completion of the reaction. Water (10 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (10 mL x 3). The mixture was then washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified on a silica gel column (petroleum ether / ethyl acetate = 16 / 1) to afford 88a (100 mg, 96% yield) as a white solid. LCMS: [M+Na] + =373.0

[0280] Step 2: Tert-butyl rel-((4-((1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide)pyridin-2-yl)sulfonyl)(methyl)carbamate (88b)

[0281] Compound 88a (53 mg, 0.15 mmol, 1.1 eq) was dissolved in dioxane (5 mL), and compound 85c (50 mg, 0.14 mmol, 1.0 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (15 mg, 0.027 mmol, 0.2 eq), cesium carbonate (89 mg, 0.27 mmol, 2.0 eq), and palladium acetate (2 mg, 0.013 mmol, 0.1 eq) were added. The reaction mixture was incubated at 105°C under nitrogen for 16 hours. LCMS monitored the reaction completion of the starting material. The reaction mixture was concentrated, and the residue was purified on a silica gel column (dichloromethane / methanol = 10 / 1) to afford compound 88b (70 mg, 80% yield) as a yellow oil. LCMS: [M+H] + =636.2

[0282] Step 3: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-N-(2-(N-methylaminosulfonyl)pyridin-4-yl)-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 88)

[0283] Compound 88b (70 mg, 0.11 mmol, 1.0 eq) was dissolved in hydrochloric acid / dioxane (4 M, 10 mL). The reaction mixture was incubated at 25°C for 4 hours. LCMS confirmed the complete reaction. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.01% FA) to afford Example 88 (4.2 mg, 7.1% yield) as a white solid. LCMS: [M+H] + =536.1.

[0284] 1H NMR (400MHz, CD3OD) δ8.54(d,J=5.6Hz,1H),8.25(d,J=2.0Hz,1H),7.81(dd, J=2.4,2.0Hz,1H),7.32-7.26(m,1H),7.06-6.95(m,1H),5.24(d,J=10.4Hz, 1H),3.92(d,J=1.6Hz,3H),3.84(d,J=10.8Hz,1H),2.63(s,3H),2.58-2.51( m,1H),2.48-2.39(m,1H),2.15-2.08(m,1H),1.49-1.48(m,1H),1.29(s,3H).

[0285] Example 89: Synthesis of Compound 89

[0286] Step 1: 1-(4-bromopyridin-2-yl)-2-fluoroethane-1-one (89b)

[0287] In a reaction flask, compound 1-(4-bromopyridin-2-yl)ethan-1-one 89a (300 mg, 1.50 mmol, 1.00 eq) was dissolved in toluene (3 mL), and tert-butyldimethylsilyl trifluoromethanesulfonate (595 mg, 2.25 mmol, 1.50 eq) and triethylamine (326 mg, 3.22 mmol, 2.15 eq) were added. The reaction solution was stirred at 80°C for 2 hours. The reaction solution was concentrated, and acetonitrile (3 mL) and a selective fluorine reagent (537 mg, 1.51 mmol, 1.01 eq) were added. The reaction solution was stirred at 25°C for 1 hour. LCMS monitored the reaction of the starting material. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 50 / 1) to obtain compound 89b (176 mg, 54% yield) as a white solid. LCMS: [M+H] + =218.0.

[0288] Step 2: 1-(4-Bromopyridin-2-yl)-2-fluoroethane-1-ol (89c)

[0289] In a reaction flask, compound 89a (176 mg, 0.81 mmol, 1.00 eq) was dissolved in methanol (5 mL) and sodium borohydride (60 mg, 1.60 mmol, 1.98 eq) was added at 0°C. The reaction mixture was stirred at 25°C for 16 hours. LCMS confirmed the completion of the reaction. The reaction mixture was concentrated and the residue was purified on a silica gel column (petroleum ether / ethyl acetate = 3 / 1) to afford compound 89c (145 mg, 81% yield) as a yellow oil. LCMS: [M+H] + =220.0.

[0290] Step 3: 4-Bromo-2-(1-((tert-butyldimethylsilyl)oxy)-2-fluoroethyl)pyridine (89d)

[0291] In a reaction flask, compound 89c (130 mg, 0.59 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (5 mL), and imidazole (149 mg, 2.18 mmol, 3.7 eq) and tert-butyldimethylsilyl chloride (151 mg, 1.00 mmol, 1.7 eq) were added. The reaction mixture was stirred at 25°C for 16 hours. LCMS monitoring confirmed the completion of the reaction. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (10 mL x 3). The mixture was then washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified on a silica gel column (petroleum ether / ethyl acetate = 20 / 1) to afford compound 89d (173 mg, 87% yield) as a colorless oil. LCMS: [M+H] + =334.0.

[0292] Step 4: rel-(1R,3R,4S,5R)-N-(2-(1-((tert-butyldimethylsilyl)oxy)-2-fluoroethyl)pyridin-4-yl)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide (89e)

[0293] In a reaction flask, compound 89d (151 mg, 0.45 mmol, 1.5 eq) was dissolved in anhydrous 1,4-dioxane (5 mL), and cesium carbonate (196 mg, 0.60 mmol, 2.0 eq), 85c (110 mg, 0.30 mmol, 1.0 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (35 mg, 0.06 mmol, 0.2 eq), and palladium acetate (5 mg, 0.03 mmol, 0.1 eq) were added. The reaction mixture was incubated at 105°C under a nitrogen atmosphere for 16 hours. LCMS monitoring confirmed the completion of the reaction. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (10 mL x 3). The mixture was then washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified on a silica gel column (petroleum ether / ethyl acetate = 2 / 1) to afford compound 89e (193 mg, 98% yield) as a colorless oil. LCMS: [M+H] + =619.3

[0294] Step 5: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(2-(2-fluoro-1-hydroxyethyl)pyridin-4-yl)-5-methyl-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 89)

[0295] Compound 89e (193 mg, 0.31 mmol, 1.0 eq) was dissolved in tetrahydrofuran (3 mL) and a tetrahydrofuran solution of tetrabutylammonium fluoride (0.4 mL) was added. The reaction mixture was allowed to react at 25°C for 3 hours. LCMS monitoring confirmed the completion of the reaction. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The mixture was then washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) and preparative separation (0.1% FA) to afford Example 89 (68.5 mg, 41.3% yield) as a white solid. LCMS: [M+H] + =505.1. 1 H NMR (400MHz, DMSO-d6) δ10.64(d,J=3.6Hz,1H),8.39(d,J=5.6Hz,1H),7.85(t,J=2.4Hz,1H),7.61(d,J =5.6Hz,1H),7.19(dd,J=16.8,8.8Hz,1H),7.12-7.06(m,1H),5.95(s,1H),5.11(d,J=8.4Hz,1H),4.80 (d,J=19.6Hz,1H),4.66(ddd,J=47.6,9.6,2.8Hz,1H),4.50(ddd,J=47.6,9.2,6.0Hz,1H),4.23(d,J=8 .4Hz,1H),3.93(d,J=2.0Hz,3H),2.46-2.35(m,2H),2.21-2.13(m,1H),1.87-1.78(m,1H),0.81(s,3H).

[0296] Example 90: Synthesis of Compound 90

[0297] Step 1: (S)-tert-Butyl (4-bromopyridin-2-yl)methyl (tetrahydrofuran-3-yl)carbamate (90c)

[0298] In a single-necked flask, compound 4-bromopicolinaldehyde 90a (100 mg, 0.54 mmol, 1.0 eq) was dissolved in 1,2-dichloroethane (5 mL). (S)-tetrahydrofuran-3-amine 90b (61 mg, 0.70 mmol, 1.3 eq), acetic acid (32.38 mg, 0.54 mmol, 1.0 eq), and sodium triacetoxyborohydride (171 mg, 0.81 mmol, 1.5 eq) were added. The reaction mixture was stirred at 25°C for 3 hours. Di-tert-butyl dicarbonate (176 mg, 0.81 mmol, 1.5 eq) was then added to the reaction mixture. The reaction mixture was stirred at 25°C for 0.5 hours. LCMS monitored the reaction completion of the starting material. The reaction mixture was concentrated, and the residue was purified on a silica gel column (petroleum ether / ethyl acetate = 4 / 1) to afford compound 90c (170 mg, 88% yield) as a yellow oil.

[0299] Step 2: rel-tert-butyl-(4-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamido)pyridin-2-yl)methyl((S)-tetrahydrofuran-3-yl)carbamate (90d)

[0300] In a single-necked flask, compound 90c (65 mg, 0.18 mmol, 1.0 eq) was dissolved in anhydrous 1,4-dioxane (5 mL). Cesium carbonate (107 mg, 0.33 mmol, 2.0 eq), compound 85c (60 mg, 0.16 mmol, 1.0 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (19 mg, 0.03 mmol, 0.2 eq), and palladium acetate (2.7 mg, 0.02 mmol, 0.1 eq) were added. The reaction mixture was incubated at 105°C under a nitrogen atmosphere for 16 hours. LCMS monitoring revealed the completion of the reaction. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (10 mL x 3). The mixture was then washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified on a silica gel column (petroleum ether / ethyl acetate = 20 / 1) to afford compound 90d (30 mg, 29% yield) as a yellow oil.

[0301] Step 3: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-N-(2-((S)-tetrahydrofuran-3-amino)methyl)pyridin-4-yl)-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 90)

[0302] Compound 90d (30 mg, 0.05 mmol, 1.0 eq) was dissolved in dichloromethane (2 mL) and trifluoroacetic acid (1 mL) was added. The reaction mixture was allowed to react at 25°C for 3 hours. LCMS confirmed the completion of the reaction. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.1% FA) to afford Example 90 (1.7 mg, 6% yield) as a white solid. LCMS: [M+H] + =542.2. 1 H NMR (400MHz, CDCl3) δ8.68 (s, 1H), 8.46 (d, J = 5.6Hz, 1H), 7.59 (s, 1H), 7.52 ( d,J=4.8Hz,1H),6.96(d,J=5.6Hz,2H),6.93-6.87(m,1H),5.02(d,J=6.4Hz,1 H),4.20(s,1H),4.00(d,J=2.4Hz,3H),3.96(s,2H),3.86-3.72(m,4H),3.55( s,1H),2.59-2.52(m,1H),2.25-2.14(m,3H),1.91-1.90(m,1H),0.90(s,3H).

[0303] Example 91: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(2-methoxyethylamino)methylpyridin-4-yl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (91)

[0304] Example 91 was prepared by a similar method using 2-methoxyethane-1-amine in place of 90b. LCMS: [M+H] + =530.2. 1 H NMR (400MHz, CDCl3) δ8.64 (s, 1H), 8.47 (d, J = 5.2Hz, 1H), 7.57-7.53 (m, 2H), 6.97-6.86 (m, 2H), 5.01(d,J=6.8Hz,1H),4.20(s,1H),4.00(s,3H),3.58(t,J=4.8Hz,2H),3.38(s,3H),2.9 5(t,J=4.8Hz,2H),2.57-2.50(m,1H),2.19-2.10(m,3H),1.94-1.89(m,2H),0.90(s,3H).

[0305] Example 92:

[0306] Step 1: 5-Bromo-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide (92b)

[0307] 4-Bromo-2-fluorobenzenesulfonyl chloride 92a (200 mg, 1.0 eq) was dissolved in THF (5 mL), cooled to 0°C, and under nitrogen, NaHMDS (0.9 mL, 1.0 M, 1.2 eq) was added dropwise. After 1 hour, a solution of tert-butyl thiazole-4-carbamate (161 mg, 1.1 eq) in THF (1 mL) was added. After slowly warming to room temperature, saturated ammonium chloride solution was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and dried by spin drying. The mixture was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to afford 5-bromo-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide 92b (150 mg, 60% yield) as a white solid. LCMS: [M+H] + =336.8,338.8.

[0308] Step 2: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(4-fluoro-3-(N-(thiazol-4-yl)aminosulfonyl)phenyl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 92)

[0309] 85c (30 mg, 0.08 mmol, 1.0 eq) was dissolved in 1,4-dioxane (5 mL), and 92b (42 mg, 0.12 mmol, 1.5 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (9.5 mg, 0.016 mmol, 0.2 eq), cesium carbonate (80 mg, 0.25 mmol, 3 eq), and palladium acetate (1.8 mg, 0.008 mmol, 0.1 eq) were added. The mixture was stirred at 105°C for 16 hours, and the filtrate was concentrated under reduced pressure. Purification by preparative isolation (0.1% FA) afforded Example 92 (2.4 mg, 4% yield) as a white solid. LCMS: [M+H] + =622.1. 1HNMR(400MHz,MeOD)δ8.53(s,1H),8.01-8.00(m,1H),7.74-7.72(m,1H),7.10-7.06(m,1H),6.99-6.96(m,1H),6.92-6.86(m,1H),6. 67(s,1H),4.95-4.93(m,1H),4.21-4.19(m,1H),3.87(s,3H),2.41-2.22(m,2H),2.14-2.07(m,1H),1.81-1.74(m,1H),0.80(s,3H).

[0310] Example 93: Synthesis of Compound 93

[0311] Step 1: Benzyl (2-(S-methylsulfonylimino)pyridin-4-yl)carbamate (93b)

[0312] 93a (2.2 g, 8.0 mmol, 1.0 eq) was weighed into a reaction flask and iodophenyl diacetic acid (8.3 g, 25.7 mmol, 3.2 eq), aminoformamide (4.3 g, 56.2 mmol, 7.0 eq), dichloromethane (150 mL), and methanol (150 mL) were added. After 16 hours at room temperature, the reaction was complete as determined by LCMS. The reaction solution was concentrated and purified by column chromatography (petroleum ether:ethyl acetate = 0-100%) to afford 93b as a yellow solid (2.3 g, 94% yield). LCMS: [M+H] + =306.4.

[0313] Step 2: (4-aminopyridin-2-yl)(imino)(methyl)-1-6-sulfonic acid ketone (93c)

[0314] Compound 93b (300 mg, 0.98 mmol, 1.0 eq) was dissolved in methanol (10 mL), and palladium on carbon (314 mg, 2.95 mmol, 3.0 eq) was added. The reaction mixture was reacted under hydrogen at 25°C for 16 hours. LCMS monitored the reaction completion. The reaction mixture was filtered, and the filtrate was collected and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain compound 93c (100 mg, 59% yield) as a white solid. LCMS: [M+H] + =172.1.

[0315] Step 3: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-N-(2-(S-methylsulfonylimino)pyridin-4-yl)-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 93)

[0316] Compound 85d (50 mg, 0.14 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and compound 93c (28 mg, 0.16 mmol, 1.2 eq), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (62 mg, 0.16 mmol, 1.2 eq), and N,N-diisopropylethylamine (35 mg, 0.27 mmol, 2.0 eq) were added. The reaction solution was stirred at 25°C for 2 hours. LCMS monitored the reaction completion. The reaction solution was concentrated to obtain a residue. The residue was purified by preparative separation (0.01% FA) to obtain Example 93 (8.2 mg, 11.6% yield) as a white solid. LCMS: [M+H] + =520.1. 1 H NMR (400MHz, CD3OD) δ8.06(d,J=5.6Hz,1H),7.33(s,1H),7.01-6.96(m,2H),6.71-6.68(m,1H),4.92(d,J=5.6Hz,1H),4.88- 4.84(m,3H),4.19(s,1H),3.95-3.93(m,3H),2.45-2.18(m,2H),2.18-1.97(m,1H),1.79-1.73(m,1H),0.85(d,J=5.2Hz,3H).

[0317] Example 94: Synthesis of Compound 94

[0318] Step 1: Benzyl (2-(N,S-dimethylsulfonylimino)pyridin-4-yl)carbamate (94a)

[0319] Compound 93b (300 mg, 0.98 mmol, 1.0 eq) was dissolved in acetonitrile (20 mL), and tetraethylsilane (283 mg, 1.96 mmol, 2.0 eq), formaldehyde (294 mg, 4.91 mmol, 5.0 eq), and trifluoroacetic acid (233 mg, 2.94 mmol, 3.0 eq) were added. The reaction mixture was reacted at 25°C for 16 hours. LCMS monitored the reaction completion. The reaction mixture was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 30 / 1) to obtain compound 94a (300 mg, 95% yield) as a colorless oil. LCMS: [M+H]+ =320.1.

[0320] Step 2: (4-aminopyridin-2-yl)(methyl)(methylimino)-1-6-sulfonic acid ketone (94b)

[0321] Compound 94a (300 mg, 0.94 mmol, 1.0 eq) was dissolved in methanol (10 mL), and palladium on carbon (300 mg, 2.82 mmol, 3.0 eq) was added. The reaction mixture was reacted under hydrogen at 25°C for 16 hours. LCMS monitored the reaction completion. The reaction mixture was filtered, and the filtrate was collected and concentrated to obtain a residue. The residue was purified on a silica gel column (dichloromethane / methanol = 10 / 1) to obtain compound 94b (150 mg, 86% yield) as a white solid. LCMS: [M+H] + =186.1.

[0322] Step 3: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(2-(N,S-dimethylsulfonyl)pyridin-4-yl)-5-methyl-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 94)

[0323] Compound 85d (50 mg, 0.14 mmol, 1.0 eq) was dissolved in anhydrous pyridine (3 mL), and compound 94b (30 mg, 0.16 mmol, 1.2 eq) was added. After mixing, phosphorus oxychloride (84 mg, 0.55 mmol, 4.0 eq) was added at 0°C. The reaction solution was stirred at 0°C for 15 minutes. LCMS monitored the completion of the reaction. The reaction solution was poured into water, extracted with ethyl acetate, and the organic phase was collected. The organic phase was dried over anhydrous sodium sulfate and concentrated to obtain a residue. The residue was purified by preparative separation (0.01% FA) to give Example 94 (14.2 mg, 16% yield) as a white solid. LCMS: [M+H] + =534.0. 1H NMR (400MHz, CD3OD) δ8.62(d,J=5.2Hz,1H),8.48(t,J=1.6Hz,1H),7.95(dd,J=2. 0,2.0Hz,1H),7.11-7.04(m,1H),7.02-6.95(m,1H),5.11(d,J=8.0Hz,1H),4.34( d,J=7.6Hz,1H),3.98(t,J=2.4Hz,3H),3.22(s,3H),2.57(s,3H),2.52-2.45(m,1 H),2.39-2.31(m,1H),2.22-2.17(m,1H),1.93-1.84(m,1H),0.90(d,J=1.2H,3H).

[0324] Example 95: Synthesis of Compound 95

[0325] Step 1: R-4-Bromo-2-(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridine (95b)

[0326] 4-Bromo-2-fluoropyridine 95a (1.0 g, 5.7 mmol, 1.0 eq) and R-2,2-dimethyl-1,3-dioxolane-4-methanol 95b (0.9 g, 6.8 mmol, 1.2 eq) were dissolved in hydrochloric acid / 1,4-dioxane (10 mL). Potassium tert-butoxide (1.9 g, 17.1 mmol, 0.1 eq), 1,1'-binaphthyl-2,2'-bis(diphenylphosphine) (0.4 g, 0.5 mmol, 0.1 eq), and palladium acetate (0.13 g, 0.5 mmol, 0.1 eq) were added. The reaction mixture was stirred at 105°C for 16 hours. After LCMS monitoring, the reaction mixture was quenched by adding 1M dilute hydrochloric acid (4 mL). The mixture was extracted with dichloromethane (10 mL × 3), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to afford compound 95c (0.5 g, 30% yield) as a white solid. LCMS: [M+H] + =288.0

[0327] Step 2: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(2,2-dimethyl-1,3-dioxolane-4-yl)methoxy)pyridin-4-yl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (95d)

[0328] 85c (500 mg, 1.37 mmol, 1.0 eq) was dissolved in 1,4-dioxane, and (R)-4-bromo-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridine 96b (592 mg, 2.0 mmol, 1.5 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (158 mg, 0.27 mmol, 0.2 eq), cesium carbonate (1.3 g, 4.1 mmol, 3.0 eq) and palladium acetate (31 mg, 0.14 mmol, 0.1 eq) were added. The reactants were stirred at 105 ° C under nitrogen for 16 hours. After the reaction was completed, the mixture was filtered. The filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 1:3) to obtain compound 95d (100 mg, 30% yield) as a yellow solid. LCMS: [M+H] + =573.2.

[0329] Step 3: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(2-(S)-2,3-dihydroxypropoxypyridin-4-yl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 95)

[0330] A mixture of 95d (100 mg, 0.17 mmol, 1.0 eq) was stirred at 25°C for 1 hour. LCMS indicated the reaction was complete. The mixture was concentrated under reduced pressure. The compound was purified by preparative purification (0.1% FA) to afford Example 95 (23.4 mg, 25% yield) as a white solid. LCMS: [M+H] + =533.2. 1 HNMR (400MHz, DMSO-d6) δ10.52 (s, 1H), 8.02 (d, J = 8.0Hz, 1H), 7.22-7.17 (m, 3H), 7.10-7. 06(m,1H),5.10(d,J=8.0Hz,1H),4.88(d,J=8.0Hz,1H),4.61(t,J=8.0Hz,1H),4.25-4.21( m,2H),4.12-4.08(m,1H),3.93(d,J=4.0Hz,3H),3.77-3.73(m,1H),3.41(t,J=4.0Hz,2H) ,2.45-2.36(m,1H),2.32-2.29(m,1H),2.19-2.12(m,1H),1.86-1.79(m,1H),0.81(s,3H).

[0331] Example 96: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(2-(R)-2,3-dihydroxypropoxypyridin-4-yl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (96)

[0332] Example 96 was prepared by a similar method using S-2,2-dimethyl-1,3-dioxolane-4-methanol instead of 95b in Example 95. LCMS: [M+H] + =533.1. 1 H NMR (400MHz, DMSO-d6) δ10.55 (s, 1H), 8.02 (d, J = 5.7Hz, 1H), 7.24-7.15 (m, 3H),7.12-7.06(m,1H),5.11(d,J=8.0Hz,1H),4.23(dd,J=9.7,4.5Hz,2H),4 .10(dd,J=10.9,6.3Hz,1H),3.93(d,J=2.2Hz,3H),3.77-3.59(m,5H),2.43 -2.29(m,2H),2.20-2.11(m,1H),1.83(td,J=10.7,7.0Hz,1H),0.81(s,3H).

[0333] Example 97: 5-((1S,3R,4S,5S)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamido)picolinamide (97)

[0334] Example 97 was prepared in a similar manner by replacing 5-amino-2-fluorobenzamide in Example 85 with 5-aminopicolinamide. LCMS: [M+H] + =486.1. 1 H NMR (400MHz, DMSO-d6) δ10.68(s,1H),8.87(d,J=2.0Hz,1H),8.25(dd,J=8.6,2.5 Hz,1H),8.01(d,J=8.6Hz,2H),7.55(s,1H),7.22-7.07(m,2H),5.16(d,J=8.1Hz,1H) ,4.25(d,J=8.1Hz,1H),3.92(dd,J=8.0,2.1Hz,4H),2.20-1.81(m,2H),0.82(s,4H).

[0335] Example 98: Synthesis of Compound 98

[0336] Step 1: 2-Bromo-1-(5-bromopyridin-2-yl)ethan-1-one (98b)

[0337] 1-(5-Bromopyridin-2-yl)ethanone 98a (2.0 g, 0.01 mmol, 1.0 eq) was dissolved in methanol (10 mL) and acetic acid (15 mL) and cooled to 0°C. A 30% solution of hydrogen bromide in acetic acid (2.8 mL) was added, and bromine (1.6 g, 0.01 mmol, 1.0 eq) in acetic acid (5 mL) was added dropwise. The reaction mixture was allowed to reach room temperature, then heated to 70°C and stirred for 1 hour. LCMS analysis indicated the reaction was complete. The mixture was concentrated under reduced pressure, and the residue was crystallized from isopropanol to afford 98b (1.0 g, 32% yield) as a yellow solid. LCMS: [M+H] + =278.9.

[0338] Step 2: 1-(5-Bromopyridin-2-yl)ethane-1,2-diol (98c)

[0339] A solution of 2-bromo-1-(5-bromopyridin-2-yl)ethanone 98b (1.0 g, 3.6 mmol, 1.0 eq) and sodium formate (1.0 g, 14.4 mmol, 4.0 eq) in ethanol (10 mL) was heated to 50°C for 3 hours. After the reaction was complete, the mixture was cooled to room temperature, and the solvent was evaporated under reduced pressure. The mixture was quenched with water (10 mL) and extracted with dichloromethane (50 mL x 3). The combined organic phases were dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was taken up in methanol (10 mL) and cooled to 0°C. Sodium borohydride (0.4 g, 10.8 mmol, 3.0 eq) was added portionwise, and the mixture was stirred at 0°C for 1 hour. The pH was adjusted to 2 by the addition of concentrated hydrochloric acid, and the solvent was removed under reduced pressure. The mixture was extracted three times with dichloromethane (50 mL) and saturated aqueous sodium bicarbonate (10 mL). The combined organic phases were dried over sodium sulfate. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to give compound 98c (350 mg, 42% yield) as a yellow solid. LCMS: [M+H] + =218.0.

[0340] Step 3: 5-Bromo-2-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine (98d)

[0341] 1-(5-Bromopyridin-2-yl)ethane-1,2-diol 98c (100 mg, 0.46 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (5 mL), and 2,2-dimethoxypropane (48 mg, 0.46 mmol, 1.0 eq) and p-toluenesulfonic acid (7.9 mg, 0.05 mmol, 0.1 eq) were added. The mixture was stirred at 25°C for 24 hours. LCMS analysis indicated the reaction was complete. The mixture was quenched with water (50 mL) and then extracted with dichloromethane (50 mL x 3). The combined organic phases were dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified using ethyl acetate (0-50%) in petroleum ether to afford 5-bromo-2-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine 98d (60 mg, 48% yield) as a yellow oil. LCMS: [M+H] + =258.0.

[0342] Step 4: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(6-(2,2-dimethyl-1,3-dioxolane-4-yl)pyridin-3-yl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (98e)

[0343] 85c (50 mg, 0.14 mmol, 1.0 eq) was dissolved in 1,4-dioxane (5 mL), and 5-bromo-2-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridine (53 mg, 0.21 mmol, 1.5 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (16 mg, 0.027 mmol, 0.2 eq), cesium carbonate (134 mg, 0.41 mmol, 3.0 eq), and palladium acetate (3.1 mg, 0.014 mmol, 0.1 eq) were added. The mixture was stirred at 105°C for 16 hours. After completion of the reaction, the mixture was quenched with water (50 mL) and then extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. Purification by silica gel chromatography (petroleum ether / ethyl acetate = 3 / 1) gave 98e (50 mg, 67% yield) as a yellow oil. LCMS: [M+H] + =543.2.

[0344] Step 5: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(6-(1,2-dihydroxyethyl)pyridin-3-yl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 98)

[0345] 98e (50 mg, 0.0184 mmol, 1.0 eq) was dissolved in hydrochloric acid / 1,4-dioxane (5 mL) and stirred at 25°C for 1 hour. The mixture was concentrated under reduced pressure. Compound Example 98 (4.2 mg, 9% yield) was obtained as a white solid by preparative (0.1% NH3). LCMS: [M+H] + =503.2. 1 H NMR(400MHz,CD3OD)δ9.15(s,1H),8.49-8.47(m,1H),7.89-7.87(m,1H),7 .12-7.07(m,1H),7.03-6.96(m,1H),5.15-5.14(m,1H),4.95-4.93(m,1H) ,4.34-4.31(m,1H),3.98-3.97(m,3H),3.84-3.76(m,2H),2.54-2.46(m,1 H),2.40-2.33(m,1H),2.25-2.17(m,1H),1.93-1.86(m,1H),0.91(s,3H).

[0346] Example 99: Synthesis of Compound 99

[0347] Example 99 was prepared in a similar manner using 5-amino-N,N-bis(3,4-dimethoxybenzyl)pyridine-2-sulfonamide in place of 34e in Example 87. LCMS: [M+H] + =522.1. 1 H NMR (400MHz, DMSO-d6) δ10.73 (s, 1H), 8.93 (d, J = 2.4Hz, 1H), 8.31 (dd, J = 8. 4,2.4Hz,1H),7.90(d,J=8.8Hz,1H),7.40(s,2H),7.23-7.16(m,1H),7.13- 7.09(m,1H),5.17(d,J=8.0Hz,1H),4.25(d,J=8.0Hz,1H),3.93(d,J=2.4Hz ,3H),2.43-2.36(m,2H),2.19-2.13(m,1H),1.87-1.80(m,1H),0.83(s,3H).

[0348] Example 100: Synthesis of Compound 100

[0349] Step 1: tert-Butyl 4-(5-bromopyridin-2-yl)-3-oxopiperidine-1-carboxylate (100b)

[0350] Dissolve tert-butyl 3-oxo-1-piperazinecarboxylate (1.37 g, 6.82 mmol, 1.2 eq) in DMF (15 mL), cool to 0°C, add sodium hydride (341 mg, 8.52 mmol, 1.5 eq), and stir for 30 minutes. Add 2-fluoro-5-bromopyridine 100a (1.0 g, 5.68 mmol, 1.0 eq), heat to 60°C, and stir for 16 hours. Add water and extract with ethyl acetate (50 mL x 3). The combined organic phases are washed with brine, dried over sodium sulfate, filtered, and dried by spin drying. The mixture is then purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to afford tert-butyl 4-(5-bromopyridin-2-yl)-3-oxopiperidine-1-carboxylate 100b (560 mg, 27.7% yield) as a white solid. LCMS: [M+H]+ = 355.9, 357.9.

[0351] Step 2: rel-tert-butyl 4-(4-((1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamido)pyridin-2-yl)-3-oxopiperazine-1-carboxylate (100c)

[0352] Compound 85c (50 mg, 0.14 mmol, 1.0 eq) was dissolved in dioxane (5 mL) and then added with 100b (65 mg, 0.18 mmol, 1.3 eq), cesium carbonate (133 mg, 0.41 mmol, 3.0 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (11 mg, 0.03 mmol, 0.2 eq), and palladium acetate (3 mg, 0.01 mmol, 0.1 eq). The reaction mixture was incubated at 105°C under a nitrogen atmosphere for 16 hours. After reaction completion, the reaction mixture was concentrated by LCMS, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1) to afford compound 100c (50 mg, 57% yield) as a colorless oil.

[0353] Step 3: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-N-(2-(2-oxopiperazin-1-yl)pyridin-4-yl)-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide (100d)

[0354] Compound 100c (50 mg, 0.078 mmol, 1.0 eq) was dissolved in trifluoroacetic acid (5 mL) and the reaction mixture was incubated at 25°C for 2 hours. LCMS monitored the completion of the reaction, and the reaction mixture was concentrated to afford compound 100d (40 mg, 95% yield) as a white solid.

[0355] Step 4: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-N-(2-(4-methyl-2-oxopiperazin-1-yl)pyridin-4-yl)-1-(trifluoromethyl)-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 100)

[0356] Compound 100d (40 mg, 0.07 mmol, 1.0 eq) and paraformaldehyde (4 mg, 0.14 mmol, 2.0 eq) were dissolved in methanol (5 mL). The reaction mixture was incubated at 25°C for 30 minutes. Sodium cyanoborohydride (8 mg, 0.14 mmol, 2.0 eq) was added, and the reaction mixture was incubated at 40°C for 1 hour. LCMS confirmed the completion of the reaction. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.1% FA) to afford Example 100 (6.7 mg, 13% yield) as a white solid. LCMS: [M+H] + =555.2. 1 H NMR(400MHz,MeOD)δ8.33(d,J=5.6Hz,1H),8.01(d,J=1.6Hz,1H),7.64(dd, J=5.6,2.0Hz,1H),7.16-6.90(m,2H),5.07(d,J=8.0Hz,1H),4.33(d,J=8.0H z,1H),4.00-3.86(m,5H),3.28(s,2H),2.92-2.80(m,2H),2.50-2.43(m,1H) ,2.40(s,3H),2.35-2.17(m,2H),1.87(td,J=10.8,6.4Hz,1H),0.90(s,3H).

[0357] Example 101: Synthesis of Compound 101

[0358] Step 1: 2-(Methylthio)pyridin-4-amine (101b)

[0359] Sodium thiomethoxide (1.9 g, 27.0 mmol, 1.7 eq) was dissolved in 1-methylpyrrolidone (10 mL) and 2-chloropyridin-4-amine 101a (2.0 g, 16.0 mmol, 1.0 eq) was added. The vessel was sealed and heated to 200°C in a microwave oven for 15 minutes. Purification by flash chromatography on silica gel eluting with 8% methanol / dichloromethane afforded 2-(methylthio)pyridin-4-amine 101b (1.5 g, 55% yield) as a yellow solid. LCMS: [M+H] + =141.0.

[0360] Step 2: 2-(Methylsulfonyl)pyridin-4-amine (101c)

[0361] 2-(Methylthio)pyridin-4-amine (100 mg, 0.7 mmol, 1.0 eq) was dissolved in tetrahydrofuran (5 mL), and m-chloroperbenzoic acid (369 mg, 2.1 mmol, 3.0 eq) was added. The mixture was stirred at 25°C for 16 hours. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain a mixture. The mixture was purified by column chromatography (dichloromethane / methanol = 10 / 1) to obtain 2-(methylsulfonyl)pyridin-4-amine 101c (30 mg, 22% yield) as a yellow solid. LCMS: [M+H] + =173.0.

[0362] Step 3: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-N-(2-methylsulfonyl)pyridin-4-yl)-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (Example 101)

[0363] 2-Methanesulfonylpyridin-4-amine 101c (14 mg, 0.082 mmol, 1.5 eq) was dissolved in anhydrous pyridine (5 mL), and 4-(3,4-difluoro-2-methoxyphenyl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxylic acid 85d (20 mg, 0.055 mmol, 1.0 eq) and phosphorus oxychloride (25 mg, 0.16 mmol, 2.9 eq) were added. The mixture was stirred at 25 ° C for 5 minutes. The filtrate was concentrated under reduced pressure. Purification by preparative (0.1% NH3) gave compound 101 (3.4 mg, 9% yield) as a white solid. LCMS: [M+H] + =521.1. 1 H NMR(400MHz,CD3OD)δ8.62(s,1H),8.48(s,1H),8.01-7.99(m,1H),7.10-7 .06(m,1H),7.03-6.96(m,1H),5.13-5.11(m,1H),4.34(d,J=6.4Hz,1H),3 .98(d,J=2.0Hz,3H),3.21(s,3H),2.51-2.45(m,1H),2.38-2.31(m,1H),2 .23-2.17(m,1H),2.03-2.00(m,1H),1.93-1.85(m,1H),0.91-0.88(m,3H).

[0364] Example 102: Synthesis of Compound 102

[0365] Step 1: (4-aminopyridin-2-yl)dimethylphosphine oxide (102b)

[0366] In a microwave oven, 2-bromopyridin-4-amine 102a (200 mg, 1.16 mmol, 1.0 eq) was dissolved in 1,4-dioxane (3 mL). Dimethylphosphine oxide 2 (180 mg, 2.31 mmol, 2.0 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (67 mg, 0.12 mmol, 0.1 eq), tris(dibenzylideneacetone)palladium (106 mg, 0.12 mmol, 0.1 eq), and potassium carbonate (320 mg, 2.3 mmol, 2.0 eq) were added. The reaction mixture was microwaved at 130°C under a nitrogen atmosphere for 2 hours. After reaction completion, the reaction mixture was concentrated by LCMS, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 8 / 1) to afford (4-aminopyridin-2-yl)dimethylphosphine oxide 102b (150 mg, 76% yield) as a yellow solid.

[0367] Step 2: rel-(1R,3R,4S,5R)-4-(3,4-difluoro-2-methoxyphenyl)-N-(2-(dimethylphosphoryl)pyridin-4-yl)-5-methyl-1-trifluoromethyl-2-oxabicyclo[3.2.0]heptane-3-carboxamide (102)

[0368] 85d (50 mg, 0.14 mmol, 1.0 eq) was dissolved in anhydrous pyridine (3 mL) and compound (4-aminopyridin-2-yl)dimethylphosphine oxide 102b (23 mg, 0.14 mmol, 1.0 eq) and phosphorus oxychloride (84 mg, 0.55 mmol, 4.0 eq) were added. The reaction mixture was allowed to react at 0°C for 1 hour. LCMS monitoring indicated that the reaction was complete. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3), then washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by preparative separation (0.05% FA) to afford compound 102 (15.8 mg, 22% yield) as a white solid. LCMS: [M+H] + =519.1. 1H NMR (400MHz, DMSO-d6) δ10.77(s,1H),8.63(d,J=5.6Hz,1H),8.28(dd,J=6.8, 2.0Hz,1H),7.85-7.82(m,1H),7.23-7.16(m,1H),7.13-7.07(m,1H),5.13(d, J=8.0Hz,1H),4.23(d,J=8.0Hz,1H),3.93(d,J=2.0Hz,3H),2.44-2.35(m,2H) ,2.19-2.12(m,1H),1.87-1.80(m,1H),1.64(s,3H),1.60(s,3H),0.82(s,3H).

[0369] Example 103: Synthesis of Compound 103

[0370] Step 1: 2-Amino-5-nitrobenzenesulfonamide (103b)

[0371] To a reaction flask, 103a (2.0 g, 8.45 mmol, 1.0 eq), ammonium carbonate (1.62 g, 16.9 mmol, 2.0 eq), copper sulfate (405 mg, 2.54 mmol, 0.3 eq), and aqueous ammonia (10 mL) were added and stirred at 120°C for 6 hours. TLC confirmed the near-complete conversion of the starting materials. The reaction solution was cooled to room temperature and poured into water to precipitate a solid. The mixture was filtered, the filter cake was washed with water, and dried to afford compound 103b (1.3 g, 71% yield) as a nitrogen-yellow solid. LCMS: 218.1 [M+H] + .

[0372] Step 2: 7-Nitro-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (103c)

[0373] 103b (600 mg, 2.76 mmol, 1.0 eq) and trimethyl orthoformate (10 mL) were added to the reaction flask and stirred at 140°C for 8 hours. TLC confirmed near-complete conversion of the starting material. The reaction mixture was cooled to room temperature and poured into water, whereupon a solid precipitated. The mixture was filtered, the filter cake washed with water, and dried to afford compound 103c (230 mg, 37% yield) as a pale solid. LCMS: 228.1 [M+H] + .

[0374] Step 3: 7-Amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (103d)

[0375] To a reaction flask were added 103c (200 mg, 0.88 mmol, 1.0 eq), iron powder (246 mg, 4.4 mmol, 5.0 eq), ammonium chloride (141 mg, 2.64 mmol, 3.0 eq), ethanol (5 mL), and water (2 mL). The mixture was stirred at 75°C for 2 hours. LCMS analysis revealed that the starting material was nearly completely converted. The reaction mixture was filtered through Celite while hot, and the filtrate was concentrated and separated by column chromatography (MeOH / DCM, 0-10%) to afford compound 103d (82 mg, 47% yield) as a light yellow solid. LCMS: 198.2 [M+H] + .

[0376] Step 4: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(1,1-dihydroxy-4H-benzo[e][1,2,4]thiadiazin-7-yl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamide (Example 103)

[0377] To a reaction flask were added 1a (144 mg, 0.406 mmol, 1.0 eq), acetonitrile (3 mL), NMI (167 mg, 2.03 mmol, 5.0 eq), and TCFH (228 mg, 0.812 mmol, 2.0 eq). The mixture was stirred for 5 minutes, followed by the addition of 103d (80 mg, 0.406 mmol, 1.0 eq). The mixture was stirred at 60°C for 12 hours. LCMS confirmed the near-complete conversion of the starting material. Water (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (MeOH / DCM, 0-10%) to afford Example 103 (63 mg, 29% yield) as a white solid. LCMS: 534.4 [M+H] + . 1 H NMR(400MHz,dmso-d6)δ12.28(s,1H),10.54(s,1H),8.22(d,J=2.2Hz,1H),7.93(d,J=2.3Hz,1H),7.82(dd,J=9.0,2.3Hz,1H),7.30(d,J=9.0Hz,1H), 7.24–7.07(m,2H),5.07(d,J=10.3Hz,1H),4.25(dd,J=10.2,7.7Hz,1H),3. 95(d,J=1.9Hz,3H),2.85–2.70(m,1H),1.61(s,3H),0.72(d,J=6.2Hz,3H).

[0378] Example 104: Synthesis of Compound 104

[0379] Step 1: 5-Nitro-1,3-dioxoisoindolin-2-yl acetate (104b)

[0380] In a single-necked flask, compound 2-hydroxy-5-nitroisoindoline-1,3-dione 104a (300 mg, 1.44 mmol, 1.0 eq) was dissolved in dichloromethane (5 mL), and acetic anhydride (221 mg, 2.17 mmol, 1.5 eq) and pyridine (228 mg, 2.88 mmol, 2.0 eq) were added. The reaction mixture was stirred at 0°C for 2 hours. LCMS monitored the reaction completion. The reaction mixture was concentrated, and the residue was purified on a silica gel column (petroleum ether / ethyl acetate = 4 / 1) to afford compound 104b (300 mg, 83% yield) as a white solid.

[0381] Step 2: 5-amino-1,3-dioxoisoindolin-2-yl acetate (104c)

[0382] In a single-necked flask, compound 104b (300 mg, 1.20 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (5 mL), and tetrahydroxydiboron (430 mg, 4.80 mmol, 4.0 eq) and 4,4'-bipyridine (19 mg, 0.12 mmol, 0.1 eq) were added. The reaction mixture was incubated at 0°C for 20 minutes. LCMS indicated that most of the starting materials had reacted. Ethyl acetate (20 mL) and water (20 mL) were then added to the reaction mixture. The organic layer was washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 1 / 1) to afford compound 104c (80 mg, 30% yield) as a yellow oil.

[0383] Step 3: rel-5-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-trifluoromethyltetrahydrofuran-2-carboxamido)-1,3-dioxoisoindoline-2-acetate (104d)

[0384] Compound 1a (100 mg, 0.28 mmol, 1.0 eq) was dissolved in anhydrous pyridine (3 mL), and compound 104c (62 mg, 0.28 mmol, 1.0 eq) and phosphorus oxychloride (173 mg, 1.13 mmol, 4.0 eq) were added. The reaction mixture was incubated at 0°C for 1 hour. LCMS monitoring confirmed the completion of the reaction. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The mixture was then washed with saturated brine, filtered, and the filtrate concentrated. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 4 / 1) to afford compound 104d (100 mg, 64% yield) as a white solid.

[0385] Step: rel-(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-N-(2-hydroxy-1,3-dioxoisoindolin-5-yl)-4,5-dimethyl-5-trifluoromethyltetrahydrofuran-2-carboxamide (Example 104)

[0386] Compound 104d (100 mg, 0.18 mmol, 1.0 eq) was dissolved in methanol (3 mL) and ammonia methanol solution (0.5 mL) was added. The reaction mixture was allowed to react at 25°C for 10 minutes. LCMS confirmed the complete reaction. The reaction mixture was concentrated, and the residue was purified by preparative separation (0.1% FA) to afford Example 104 (28.2 mg, 29% yield) as a white solid. LCMS: [MH] - =513.1.

[0387] 1 H NMR (400MHz, DMSO-d6) δ10.77(s,1H),8.14(d,J=1.6Hz,1H),7.94(dd,J=8.0,2.0Hz,1H),7.78(d,J=8.0Hz,1H),7.21-7.14(m ,2H),5.12(d,J=10.0Hz,1H),4.29-4.25(m,1H),3.95(d,J=2.0Hz,3H),2.82-2.74(m,1H),1.61(s,3H),0.74(d,J=5.6Hz,3H).

[0388] Table 1: The following compounds were prepared using the corresponding reagents as starting materials and following procedures similar to those described in the above examples.

[0389] Biological activity test 1: In vitro inhibition of Nav 1.8 by the compound

[0390] Manual patch clamp was used on HEK293 cells stably expressing human Nav 1.8. After the Nav 1.8 current stabilized, the magnitude of the Nav 1.8 current was compared before and after the compound was administered to obtain the effect of the compound on the Nav 1.8 channel.

[0391] Test compounds were dissolved in DMSO to a 9 mM stock solution and dissolved in the extracellular fluid at the desired concentration on the day of testing. The extracellular fluid composition included (mM): NaCl, 137; KCl, 4; CaCl2, 1.8; MgCl2, 1; HEPES, 10; Glucose, 10; pH 7.4 (titrated with NaOH). All reagents were purchased from Sigma (St. Louis, MO).

[0392] Cells were clamped at -80 mV and depolarized to 10 mV with a 10-millisecond square wave to elicit Nav 1.8 currents, repeated every 5 seconds. The maximum current evoked by the square wave was measured. Once the current stabilized, the test compound (dissolved in the extracellular fluid at the desired concentration) was perfused. After stabilization, the strength of the compound's Nav 1.8 blockade was calculated based on the currents before and after compound perfusion. pCLAMP 10 (Molecular Devices, Union City, CA) was used. Current stability refers to the ability of the current to remain within a limited range over time.

[0393] Table 1: Inhibition rate determination (inhibition rate at 100 nM concentration / %: A>=50, B<50)

[0394] The same method was used to determine the inhibition rate / % of other compounds of the present invention on Nav 1.8 at a concentration of 100 nM, indicating that the compounds of the present invention have excellent sodium channel regulating activity (>=50%) and can be used to treat diseases related to sodium channel regulation.

[0395] Biological activity test 2: In vitro inhibition IC of Nav 1.8 by test compounds 50

[0396] Experimental testing was performed using a CHO cell line stably expressing the Nav1.8 sodium channel. Gene information: Sodium channel, voltage-gated, type 8, alpha (SCN10A), cDNA strictly similar to GenBank accession number: NM_006514.

[0397] Before patch clamp testing, cells were detached with 0.25% Trypsin-EDTA and 6.5 × 10 3 The cells were plated on coverslips and cultured in 24-well plates (final volume: 500 μL). After 18 hours, the assay was performed.

[0398] Electrophysiological recording solutions: Extracellular solution: K-007-1, 140 mM NaCl, 3.5 mM KCl, 1 mM MgCl₂·6H₂O, 2 mM CaCl₂·2H₂O, 10 mM D-glucose, 10 mM HEPES, 1.25 mM NaH₂PO₄·2H₂O, pH adjusted to 7.4 by NaOH. Intracellular solution: Nav-001-2, 50 mM CsCl, 10 mM NaCl, 10 mM HEPES, 60 mM CsF, 20 mM EGTA, pH adjusted to 7.2 by CsOH. The extracellular solution has a shelf life of 2 weeks. After preparation, the intracellular solution is aliquoted into 1 mL tubes and stored frozen at -20°C. Freshly thawed intracellular solution is used daily for each experiment. All intracellular solution should be used within 3 months. After 3 months, discard the old intracellular solution and prepare a fresh one.

[0399] Patch clamp detection: The voltage stimulation protocol for whole-cell patch clamp recording of Nav1.8 sodium current is as follows: After the whole-cell seal is formed, the cell voltage is clamped at -120mV for 30ms. The clamping voltage is depolarized to 0mV and maintained for 50ms, and then the voltage is restored to -50mV (the specific voltage refers to the half-inactivation voltage of the IV test) and maintained for 5s. Then the cell membrane potential is restored to -120mV, maintained for 20ms, and then depolarized to 0mV again, maintained for 50ms, and finally restored to the clamping voltage of -120mV, maintained for 30ms. Data is collected repeatedly every 20ms. The effect of the drug on the peak of the sodium current is observed. The experimental data are collected by an EPC 10 amplifier (HEKA) and stored in the PatchMaster (HEKA) software.

[0400] Recording electrodes are drawn from capillary glass tubes using a microelectrode puller. The electrodes, filled with intracellular fluid, are placed in an electrode holder. Under an inverted microscope, the microelectrode manipulator is used to immerse the electrodes in extracellular fluid and record the electrode resistance (Rpip). The electrodes are placed in contact with the cell surface and negative pressure is applied to create a high-resistance seal (GΩ). Fast capacitance compensation is then performed, and negative pressure is continued to rupture the cell membrane, establishing whole-cell recording mode. Slow capacitance compensation is then performed, and experimental parameters such as membrane capacitance (Cm) and series resistance (Rs) are recorded. No leakage compensation is performed.

[0401] When the Nav1.8 current recorded in the whole cell is stable, the drug is administered. After each drug concentration is applied for 5 minutes (or the current is stable), the next concentration is detected. Multiple concentrations are detected for each test compound. The coverslip with cells is placed in a recording bath under an inverted microscope. The blank control external solution and the working solution of the test compound are passed through the recording bath from low concentration to high concentration by gravity perfusion to act on the cells. A peristaltic pump is used for liquid exchange during recording. The current detected for each cell in the external solution without the compound serves as its own control group. At least three cells are used for each concentration and the test is repeated three times independently. All electrophysiological experiments were performed at room temperature.

[0402] Data analysis: First, normalize the current after each drug concentration and the blank control current Then calculate the inhibition rate corresponding to each drug concentration The mean (Mean), standard deviation (SD) and standard error (SE) of the inhibition rate at each concentration were calculated. Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC 50 -X)*HillSlope))

[0403] The IC of each compound was calculated using the above equation 50 values, and a nonlinear fitting was performed for the dose-dependent effect, where IC 50 IC is the half inhibitory concentration. 50 Calculations and curve fitting were performed using GraphPad Prism software.

[0404] The same method was used to test the inhibitory effects of other compounds of the present invention on Nav 1.8, which showed that the compounds of the present invention had a good inhibitory effect on Nav 1.8.

[0405] Biological activity test 3: efficacy of the compound on the mouse incisional pain model

[0406] Model establishment: Under isoflurane anesthesia and routine disinfection, a 0.5 cm long longitudinal skin incision was made with a blade on the plantar surface of the left hindfoot approximately 0.2 cm distal to the tibiotalar joint, extending toward the toes. The plantar muscles were separated, slightly elevated, and then longitudinally incised, taking care not to damage the muscle origin and insertion. The incision was sutured with interrupted horizontal 5-0 nylon suture (two stitches).

[0407] Solvent: The solvent used for the test compound was 5% DMSO + 10% Solutol + 85% Saline, and the solvent used for the positive compound TRV-130 was 10% ethanol + 10% cremophor + 80% water.

[0408] Reference compound 1 is compound 7 in WO2021113627A1, which was synthesized according to the method in WO2021113627A1.

[0409] Dosage method and frequency: The positive control compound TRV-130 was administered intravenously once a day; the other groups were administered orally once a day.

[0410] Experimental grouping: Before modeling, eight animals were randomly selected as the sham-operated group after excluding abnormal animals based on the baseline PWT value. Eight animals in each drug-treated group underwent surgical modeling, and the remaining animals were kept as backup. After surgery, the animals were further grouped based on their pre-drug pain threshold (PWT). If an animal's PWT value was found to be abnormal after surgery, an animal was randomly selected from the backup group to re-establish the model.

[0411] Mechanical pain threshold measurement: The mechanical pain threshold was measured before modeling; the mechanical pain threshold was measured before drug administration 2.5 h after modeling. Oral administration was performed after the measurement, and the mechanical pain threshold was measured 2 h after drug administration. The measurement position was within the surgical incision position. Each animal was measured 3 times, with an interval of 3-5 minutes each time, and the average value was taken.

[0412] Data Analysis: Data were compiled using Office Excel 2013 and GraphPad Prism 6.0, and are presented as mean ± SEM (standard error of the mean). One-way ANOVA was used for analysis, using the Tukey test for significant differences between groups. Two-group comparisons were performed using a two-tailed T-test, with p < 0.05 considered significant between the two groups. When a few significant differences were detected within the groups, GraphPad Prism 9.0 was used to identify outliers, excluding those with significant differences (Q = 5%). Data from animals excluded from efficacy studies were excluded from the statistical analysis.

[0413] The experiments showed that the compound of the present invention had a higher pain threshold (PWT) than the control compound 1 at different doses (8 mg / kg, 25 mg / kg, 75 mg / kg), and could effectively inhibit pain.

Claims

1. Compounds of Formula I or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R a1 、R a2 、R a3 Each is independently selected from hydrogen, halogen, hydroxy, C1-C5 alkyl, C1-C5 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, -N(R c3 R c4 ) m , or any two adjacent R a1 、R a2 、R a3 Connected to form a 5-7 membered ring, the 5-7 membered ring can be a saturated or unsaturated carbocyclic ring or heterocyclic ring; the heterocyclic ring optionally contains one or more N, O, S (=O) m heteroatoms; R b1 、R b2 、R b3 、R b4 Each is independently selected from hydrogen, halogen, hydroxy, C1-C5 alkyl, C1-C5 alkoxy; or R b1 、R b2 、R b3 、R b4 Any two are connected to form a 3-7 membered ring; M1, M2 are independently selected from C, O, S(=O) m NR n , where R n Optionally selected from hydrogen, C1-C5 alkyl; Ring A is A1 or A2: Any single or double bond X1, X2, X3, X4, X5 are each independently selected from a bond, C, N, O, C=O, S(=O) m ; Y1 and Y2 may be the same or different and may be selected from C atoms or N atoms; R c1 、R c2 Each is independently selected from hydrogen, halogen, cyano, hydroxy, amino, C1-C5 alkyl, C1-C5 alkoxy, -S(=O) m -R c3 R c4 、-C(=O)-NR c3 R c4 、-C(=S)-NR c3 R c4 、-N(R c3 R c4 ) m 、-P(=O) m -R c3 R c4 、-C(=N)-NR c3 R c4 、-S(=O)2NR c3 R c4 、-C1-C5 alkyl NR c3 R c4 、-S(=O)(=NR c3 )R c4 ; R c3 、R c4 Each is independently selected from hydrogen, hydroxy, amino, C1-C5 alkyl, C1-C5 alkoxy, 3-7 membered ring, or R c3 、R c4 Connect to form a 3-7 membered ring; m and n are 0, 1 or 2; The alkyl, alkoxy, cycloalkyl, cycloalkoxy, 5-7 membered ring, 3-7 membered ring can be optionally substituted with one or more deuterium, halogen, hydroxyl, cyano, oxo, C1-C5 alkyl, C1-C5 alkoxy, and amino groups.

2. The compound of formula I according to claim 1, R a1 、R a2 、R a3 Each is independently selected from fluorine, chlorine, methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethoxy, difluoromethoxy, and amino.

3. The compound of formula I according to claim 1, any two adjacent R a1 、R a2 、R a3 Connected to form a 5- or 6-membered carbocyclic or heterocyclic ring.

4. The compound of formula I according to claim 1, R b1 、R b2 R b3 、R b4 Each is independently selected from hydrogen, methyl, trifluoromethyl, ethyl, methoxy, and ethoxy.

5. The compound of formula I according to claim 1, R b1 、R b2 、R b3 、R b4 Any two of them can be connected to form a 3-membered ring, a 4-membered ring, or a 5-membered ring.

6. The compound of formula I according to claim 1, wherein ring A has the following structure:

7. The compound of formula I according to claim 1, wherein the formula I has a structure as shown in formula IA or formula IB:

8. The compound of formula I according to claim 1 or 7, having the following structure:

9. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt, stereoisomer thereof and a pharmaceutically acceptable excipient.

10. Use of the pharmaceutical composition according to claim 9 or the compound of formula I according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof in the preparation of a medicament for treating, preventing or alleviating voltage-gated sodium channel-related diseases. The use according to claim 10, wherein the disease is pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or arrhythmia.

Citation Information

Cited By

  • Polysubstituted pyrrolidine derivative as well as preparation method and application thereof

    CN119371405A